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Non-melanoma skin cancers (NMSCs) are the most common form of cancer in the 
United States with an estimated 3.5 million new cases each year. Surgical excision is the 
main treatment for NMSC, but leaves the potential for disfiguring scars and does not fully 
reduce the risk of recurrence since the surrounding tissue is also sun damaged and may 
contain tumor-promoting mutations. By understanding the molecular etiology of NMSC we 
may be able to expand treatment options to more than just resection. Normal epidermal 
development is dependent upon the expression of the transcription factor p63. Amplification 
of the ΔNp63α isoform is also frequently observed in NMSC, making it an excellent 
candidate for understanding the etiology of NMSC. 
This dissertation focuses on how ΔNp63α influences keratinocyte proliferation by 
regulating phosphatase and tensin homologue deleted on chromosome ten (PTEN). The 
tumor suppressor PTEN has been called “the second guardian of the genome” for its 
widespread role in preventing tumor formation and is second only to p53 in the frequency of 
observed mutations or loss in human cancers. The studies presented in this dissertation 
demonstrate that ΔNp63α is able to maintain the proliferative potential of keratinocytes by 
activating Akt through transcriptional repression of PTEN. The inhibition of PTEN by 
ΔNp63α was independent of any repressive effects of ΔNp63α towards other p53 family 
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members. Since the discovery of nuclear PTEN the tumor suppressive functions of PTEN 
have expanded to include induction of cell cycle arrest, accentuation of apoptotic signaling 
and maintenance of chromosome stability. ΔNp63α was also shown to inhibit the nuclear 
localization of PTEN, which may further the increase the proliferative potential of basal layer 
keratinocytes. Inhibition of NEDD4-1 by ΔNp63α was implicated in reducing the 
ubiquitination of PTEN, thereby preventing its import into the nucleus. The studies presented 
here also identify a novel pool of PTEN that is localized to centrosomes only during mitosis. 
Coordinated control of both Akt and PTEN regulate centrosome composition and integrity 
during mitosis and provides insight into how PTEN functions as a multifaceted tumor 
suppressor. The importance of the ΔNp63α/PTEN/Akt signaling loop in epidermal biology 
was highlighted by the significant disruption of ΔNp63α and PTEN levels in NMSC. 
Altogether, these studies provide important molecular insight into the control of keratinocyte 
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A. Non-melanoma skin cancers. 
Non-melanoma skin cancers (NMSCs) are the most common form of cancer in 
the United States with an estimated 3.5 million new cases each year (Rogers et al., 2010). 
Exposure to ultraviolet B (UVB) light is the leading cause of NMSC and changes in 
social behavior including increased usage of tanning beds have contributed to the rise in 
the NMSC (Markovic et al., 2007). Basal cell carcinomas (BCC) represent ~60% of all 
NMSCs, while squamous cell carcinomas (SCC) represent ~40% (Society, 2010). The 
treatment cost of NMSC to Medicare alone is $285 million per year, making it the fifth 
most expensive cancer to treat with few treatment options other than surgical resection 
(Housman et al., 2003; Joseph et al., 2001). Both BCC and SCC arise from keratinocytes 
of the epidermis, but have distinct phenotypes and aggressive behaviors.  
Basal cell carcinomas are thought to arise from the basal layer of the epidermis 
and are rarely metastatic, usually only showing local invasion. The keratinocyte 
subpopulations of origin for squamous cell carcinoma are hotly debated, but have 
phenotypes akin to the spinous layer of the epidermis (Figure 1). Although the propensity 
for metastasis is generally low (< 5%) for all NMSC, SCC can become metastatic, often 
growing along nerve sheaths within the dermis (termed perineural invasion) (Czarnecki et 
al., 1994). Removal of affected tissue is the primary and most effective treatment for both 
BCC and SCC, although the rare cases of metastatic NMSC require radiation or platinum 
based therapies in addition to surgery. Mohs Micrograph Surgery (MMS) is the most 
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effective treatment option, especially for high risk NMSC, with 5 year cure rates of ~98% 
(Rowe et al., 1989a; Rowe et al., 1989b). Due to the time consuming nature and advanced 
training required to perform MMS, simple excision is the main treatment of NMSC. 
Standard curettage or resection surgeries can also leave potentially disfiguring scars, but 
do not fully reduce the risk of recurrence since the surrounding tissue is also sun 
damaged and may contain tumor-promoting mutations. In fact, patients with BCC and 
SCC are at a 19% and 30% respective risk of developing a secondary primary cancer and 
are 2.4- to 3-fold more likely to later develop melanoma (Krueger and Williams, 2010).  
The increasing frequency of skin cancers combined with the lack of treatment options 
exemplifies the need for increased research into the etiology of skin cancer. By 
understanding the development of NMSC we may be able to expand treatment options to 
more than just resection. To understand the etiology of NMSC we must first identify 
molecular pathways involved in keratinocyte proliferation, as these are cells of origin for 
both BCC and SCC. Commitment to the keratinocyte lineage is dependent upon the 
expression of the transcription factor p63 (Mills et al., 1999; Yang et al., 1998; Yang et 
al., 1999). The frequent overexpression of p63 in NMSC and the requirement of p63 for 
the development of the epidermis make it an excellent candidate for elucidating the 
molecular underpinnings of NMSC (Bircan et al., 2006; Choi et al., 2002; Di Como et al., 
2002; Mills et al., 1999; Sakiz et al., 2009; Yang et al., 1998; Yang et al., 1999). If we 
know how p63 influences keratinocyte development and proliferation we could 
potentially create preventative therapies and improve current NMSCs treatment 
strategies. This dissertation seeks to determine how p63 influences keratinocyte 








Figure 1: Structure of human skin. (A) Hematoxylin and eosin (H&E) staining of 
normal adult skin. The locations of the sub-layers of two main components of skin, the 
epidermis and dermis, are designated by braces. (B) H&E staining of the two most 
common types of non-melanoma cancers that arise from the epidermis: basal cell (left) 








Figure 2: Structure of p63. A) Schematic of the p63 gene showing alternative promoters 
at the 5’-terminus and splice variations (α, β, γ, δ, and δ) of the 3’-terminus. Exons 
comprising functional domains are color coded as follows: dark blue, full length 
transactivation (TA) domain; purple, ΔN-specific TA domain; green, DNA binding 
domain; red, oligomerization domain (OD); light blue, sterile alpha motif (SAM); and 
yellow, transcription inhibitory domain (TID). (B) Diagram of the p63 protein isoforms 




B. Structure of p63.  
Initially discovered in 1999 because of high sequence homology to the tumor 
suppressor p53, the transcription factor p63 was quickly identified as a major contributor 
to epithelial morphogenesis rather than a canonical tumor suppressor like p53 (Mills et 
al., 1999; Yang et al., 1998; Yang et al., 1999). Analysis of the Trp63 gene found that 
there are at least nine possible p63 isoforms, depicted in Figure 2, due to alternative 
promoter usage and 3’ terminal splicing (Mangiulli et al., 2009; Yang et al., 1998). 
Isoforms using the P1 promoter, referred to as TAp63 isoforms, contain the full length 
amino-terminal transactivation (TA) domain while use of the internal P2 promoter yields 
isoforms with a unique, truncated transactivation domain known as ΔNp63. A third form 
of p63, unique to spermatozoa of great apes, is generated from a cryptic promoter 
upstream of P1 to yield the so-called germ-cell TAp63 (GTAp63) (Beyer et al., 2011). 
Expression of the full carboxy-terminus of p63 generates p63α isoforms (TAp63α or 
∆Np63α) while alternative splicing yields the sequentially shorter p63β or p63γ isoforms 
(TAp63β, TAp63γ and ΔNp63β and ΔNp63γ) (Yang et al., 1998). Recently, two 
additional isoforms of ΔNp63, ΔNp63δ and ΔNp63ε, have been identified (Mangiulli et 
al., 2009). Delta and epsilon isoforms of TAp63 have not yet been detected in vivo.  
All p63 isoforms share the same DNA binding domain (DBD). Due to the high 
sequence homology (65%) to the DBD of p53, p63 proteins are capable of binding to the 
p53 responsive elements in the promoters of target genes (Yang et al., 1998). Like p53, 
p63 is only transcriptionally active when bound as tetramers that are linked through the 
oligomerization domain (OD) (Brandt et al., 2009; Joerger et al., 2009; Natan and 
Joerger). Because the OD is shared by all p63 isoforms, p63 can form homo-tetramers of 
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a single isoform or hetero-tetramers of TAp63 and ΔNp63 (Joerger et al., 2009). The 
transcription inhibitory domain (TID) of TAp63α physically interacts with the full-length 
transactivation domain to prevent TAp63α dimers from joining to form a transcriptionally 
active tetramer (Deutsch et al., 2011; Serber et al., 2002). While the ΔNp63α isoform also 
contains a TID, the truncated transactivation domain cannot interact with the TID thus 
allowing the ΔNp63α isoform free to constitutively form tetramers (Deutsch et al., 2011).  
Both TAp63α and ΔNp63α also contain a sterile-alpha-motif (SAM) within the 
carboxy-terminus which is not found in any of the shorter isoforms (Thanos and Bowie, 
1999). The SAM domain is thought to aid in protein-protein interactions with mutations 
in this domain being associated with Ankyloblepharon–Ectodermal dysplasia–Clefting 
syndrome (Rinne et al., 2009; Thanos and Bowie, 1999).  
C. Role of p63 isoforms in skin development. 
Proper development and maintenance of a stratified epidermis requires the correct 
expression of the transcription factor p63 (Mills et al., 1999; Yang et al., 1998; Yang et 
al., 1999). Unlike its sister protein p53, p63 has a well-defined role in development. Mice 
deficient of all p63 isoforms fail to form a stratified epidermis, causing severe 
dehydration and ultimately death, in addition to failed formation of limbs, craniofacial 
bones and mammary or prostate tissue (Mills et al., 1999; Yang et al., 1999). While 
ΔNp63α is the predominant isoform in adult epithelia, with the exclusion of germ cells, 
the contribution of the different isoforms during skin development is complex (Beyer et 
al., 2011; Di Como et al., 2002; Suh et al., 2006). 
As early as day embryonic day 7.5 expression of the TAp63 isoforms can be 
detected in mouse embryonic ectoderm (Koster et al., 2004). However, by embryonic day 
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9.5 the ΔNp63α isoform becomes the most predominant isoform and continues to drive 
the expansion of the epidermis into a fully differentiated and stratified tissue (Koster et 
al., 2004; Yang et al., 1998). Despite the differences in the onset of expression, the exact 
roles of the TAp63 and ΔNp63 isoforms during development are somewhat controversial. 
Using thymic epithelia from wildtype and p63-/- mice as a model system, Senoo et al. 
found that ΔNp63α is critical for proliferation of epithelial cells, but not for lineage 
commitment or differentiation (Senoo et al., 2007). Koster et al. found that the TAp63 
isoforms were critical for epithelial commitment and the ΔNp63 isoforms were required 
for proliferation and terminal differentiation of the epidermis (Koster et al., 2004; Koster 
et al., 2009; Senoo et al., 2007). Complicating the story still, the Aberdam group found 
that ΔNp63, not TAp63, was essential for epidermal commitment using an in vitro 
embryonic stem cell system (Medawar et al., 2008). According to this same study, 
however, ΔNp63 may not be necessary for commitment of the ectoderm to other 
epithelial lineages (Medawar et al., 2008).  
The isoform controversy is somewhat resolved by the re-evaluation of the initial 
strains of p63-knockout mice as well as the development of p63 isoform specific 
knockout mice. Soon after the discovery of the p63 gene, two groups simultaneously 
generated p63 knockout mice using different stem cell technologies (Mills et al., 1999; 
Yang et al., 1999). The McKeon laboratory generated a true p63 knockout mouse by 
replacing exons 6-8, which encompass the shared DNA binding domain, with a neomycin 
cassette thus ablating all isoforms of p63 protein (Yang et al., 1999). The “knockout” 
strain developed by Mills et al, dubbed Bdrm2, employed a gap-repair mechanism that 
truncated Trp63 after exon 10 through the insertion of a vector homologous to exons 5-10 
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(Mills et al., 1999). This Bdrm2 mutant strain resulted in deletion of the alpha, beta and 
gamma isoforms of p63, which were the only isoforms known at the time. While both the 
McKeon laboratory’s and the Bdrm2 p63 homozygous knockout mice are nearly 
phenotypically identical in that the mice lack appendages, secondary sex organs and have 
severely retarded craniofacial development, it was later found that Bdrm2-p63 mouse still 
produced epidermal “micro-rafts” as well as positively staining for p63 in the simple 
epithelia of the internal mucosal tissues. The Bdrm2-mutation failed to disrupt the 
expression of ΔNp63δ and ΔNp63ε, thus allowing for a minute amount of epithelial 
development (Romano et al., 2009). These micro-rafts are sections of fully stratified 
epidermis, but are rare, small (negligible to the naked eye), and insufficient to prevent 
neo-natal death due to dehydration. Contrary to in vitro studies by Koster and Senoo, the 
re-evaluation by Wolf et al. of the Bdrm2-p63 strain of mice implicated that the ΔNp63 
isoforms may be sufficient to drive epidermal commitment, proliferation and 
differentiation, but that the ΔNp63δ and ΔNp63ε isoforms are relatively weak regulators 
of these processes (Koster et al., 2004; Senoo et al., 2007; Wolff et al., 2009). It would be 
another decade before this hypothesis was tested through the generation of isoform 
specific p63 knockout mice. 
 Again, two groups simultaneous developed TAp63 specific knockout mice using 
two different embryonic stem cell ablation technologies. While there exist differences in 
the wound healing ability of the two TAp63-/- mice strains, namely that the strain 
developed by Dr. Elsa Flores developed cutaneous ulcers while the strain from the 
McKeon group showed no such skin fragility, both TAp63-/- mice strains were viable 
with fully developed skin, secondary sex organs and appendages (Su et al., 2009; Suh et 
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al., 2006). Since the TAp63-/- mice did not recapitulate any of the phenotypes of the 
global p63-/- mice, it would suggest that it is truly the ΔNp63 isoforms that are necessary 
for epithelial proliferation and epidermal commitment and differentiation.  
The importance of the ΔNp63 isoforms in the epithelial development is further 
highlighted by the recent production of ΔNp63-/- mice through replacement of the 
ΔNp63 specific 3’ exon with a GFP cassette (Romano et al., 2012). Disruption of the 
ΔNp63 isoforms did not affect the expression or function of TAp63, but severely 
disrupted epithelial development. The ΔNp63-/- mice, similar to the global p63-/- strains, 
failed to fully develop limbs or secondary sex organs and had major craniofacial 
abnormalities. Unlike the p63-/- mice, the ΔNp63-/- produced a single layer, primordial 
epidermis over much of the animal. The primordial epidermis, however, was non-
functional due to disorganized differentiation, deficient proliferation, and lack of any 
barrier function. While neither TAp63-/- or ΔNp63-/- mice fully recapitulated the 
phenotype of the global p63-/- mice strains, the ΔNp63-/- strain had very similar defects 
in epithelial morphogenesis suggesting that the ΔNp63 isoforms are the master regulators 
of epithelial commitment and epidermal development with the TAp63 isoforms 
performing a supportive role in maintaining epidermal homeostasis during wounding.  
While there remains much to be teased apart about the roles of TAp63 versus 
ΔNp63 isoforms during epidermal development, it is well accepted that ΔNp63α is the 
predominant isoform in most adult epithelial tissues. In fact, TAp63 is only readily 
detected in germ cells (TAp63α in ovaries or GTAp63 in spermatozoa) where it serves to 
induce apoptosis and preserve the fidelity of the germ line upon genotoxic insult (Beyer 
et al., 2011; Suh et al., 2006). ΔNp63α, on the other hand, is detected in the basal layer of 
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most epithelia with the highest expression in the basal layer of the epidermis and outer 
root sheath of hair follicles (Figure 3) (Di Como et al., 2002). Since NMSC primarily 
affect individuals over the age of 50 and ΔNp63α is the major physiologic isoform in  
adult tissue, emphasis will be put on examining the molecular mechanisms of ΔNp63α in 









Figure 3: ΔNp63α is restricted to the basal layer of healthy skin. The localization of 
p63 in mouse skin was determined by co-localization with epidermal markers of 
differentiation. The left panel shows co-localization with the basal layer marker keratin 5 
(K5, green). No co-localization of p63 with the spinous layer keratin 1 (K1, middle 
panel), nor the granulosum specific marker involucrin (Inv, right panel) was observed. 
Formalin fixed paraffin embedded skins sections and all antibodies used to differentially 
stain the epidermis, including the ΔNp63 isoform specific antibody RR14, were donated 




D. Transcriptional activity of ΔNp63α. 
ΔNp63α levels are highest in the basal layer of the epidermis where it serves to 
maintain the proliferative nature of the basal layer stem cells by repressing the expression 
of many pro-apoptotic genes while enhancing expression of pro-survival genes (Barbieri 
et al., 2005; Senoo et al., 2002; Westfall et al., 2003; Yang et al., 1998). ΔNp63α controls 
gene expression by binding to either p53 or p63-specific responsive elements in the 
promoter of target genes (Osada et al., 2005). The exact p63-specific consensus sequence 
is more ambiguous than the p53 response element. Luciferase reporter studies with 
TAp63γ found that a guanine in the fifth position of the core, along with a several 
mismatches in the flanking purine (RRR) and pyrimidine (YYY) sequences of the 
canonical RRRCWWGYYY p53 response element, distinguishes the p63 responsive 
element from that of p53 (Osada et al., 2005). Studies by Ortt and Sinha, however, 
determined the p63 consensus sequence to be CA(T)TG core and AT-rich 5′ and 3′ 
flanking sequences when recombinant ΔNp63α was used in electromobility shift assays 
(Ortt and Sinha, 2006). Crystallographic studies between DNA and the p63 DBD support 
the conclusion by Ortt that the preferred p63 consensus sequence is a core CA(T)TG 
flanked by AT-rich regions (Chen et al., 2011). Despite their differences, the studies by 
Osada et al. and Ortt and Sinha both demonstrated a large heterogeneity in sequences to 
which p63 proteins can bind; imbuing p63 proteins with the ability to bind an extensive 
cohort of DNA elements (Ortt and Sinha, 2006; Osada et al., 2005).  
The ability of ΔNp63α to bind to p53 and p63 specific responsive elements allows 
ΔNp63α and p53 to differentially affect the expression of the same genes. For example, 
p53 induces the expression of p21 to induce cell cycle arrest, while ΔNp63α suppresses 
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the expression of p21 to maintain proliferation (el-Deiry et al., 1993; Westfall et al., 
2003). Additionally, analysis of the p21 promoter demonstrated that when co-expressed, 
ΔNp63α can act in a dominant negative manner to prevent the pro-apoptotic 
transcriptional activities of p53 and the TAp63 isoforms by competing for the same 
binding sites (Yang et al., 1998). ΔNp63α can also form heterotetramers with the TAp63 
isoforms to inhibit the growth suppressive activities of TAp63 (Joerger et al., 2009).  
E. ΔNp63α in cancer. 
Amplified levels of ΔNp63α have been observed in multiple types of squamous 
cell and basal cell carcinomas (Bircan et al., 2006; Choi et al., 2002; Di Como et al., 
2002; Hu et al., 2002; Park et al., 2000; Parsa et al., 1999; Sakiz et al., 2009). 
Overexpression of ΔNp63α in SCC most commonly occurs through genomic 
amplification (Hibi et al., 2000). More invasive, poorly differentiated SCC show 
decreased expression of p63 as compared to well-differentiated, less invasive cancers 
(Fukushima et al., 2009; Koga et al., 2003; Morita et al., 2005; Sakiz et al., 2009; Urist et 
al., 2002). It is currently unclear to what extent, ΔNp63α plays during early tumor 
development, but its function may be unnecessary, or even detrimental, to later stages of 
tumor progression and invasion as evidenced from its absence in more invasive cancers. 
Further solidifying the anti-invasive role of ΔNp63α, it is known that p63 represses the 
expression of many genes involved with invasion while inducing the expression of genes 
involved with repression of invasion, such as the vitamin D receptor (Barbieri et al., 
2006; Kommagani et al., 2009). Furthermore, silencing of p63 increases the transforming 
potential of p53 null mouse embryonic fibroblasts (Lang et al., 2004).  
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Consistent with the idea of ΔNp63α being a weak oncogene, several transgenic 
mouse models demonstrated that overexpression of ΔNp63α alone resulted in hyperplasia 
and stem cell loss but were insufficient to generate tumors (Romano et al., 2009; Romano 
et al., 2010). However, Keyes et al. found that allograft studies utilizing primary 
keratinocytes overexpressing ΔNp63α and oncogenic Ras could form locally invasive 
SCC, implying that ΔNp63α can be oncogenic (Keyes et al.).  
The frequency of ΔNp63α amplification combined with the inability of ΔNp63α 
alone to initiate tumor formation would suggest the reliance on additional oncogenic 
pathways in the development of NMSC. The Akt pathway is one of the most frequently 
activated proliferation pathways in human cancers. Hyperactivation of Akt is seen in both 
BCC (Paolini et al., 2011) and SCC (Hafner et al., 2010). Interestingly, activation of the 
Akt pathway in SCC was not found to be associated with mutations in Akt itself or 
upstream kinases, suggesting alternative means of Akt activation in NMSC (Hafner et al., 
2010). 
F. ΔNp63α and the PTEN/ Akt pathway. 
In addition to repressing the expression of many pro-apoptotic genes while 
enhancing expression of pro-survival genes, ΔNp63α is also able to stimulate the 
activation of Akt, a powerful regulator of cell growth and survival (Barbieri et al., 2005; 
Ogawa et al., 2007; Senoo et al., 2002; Westfall et al., 2003; Yang et al., 1998). By 
phosphorylating a myriad of target proteins, the kinase Akt facilitates survival, enhances 







Figure 4: Schematic of the canonical Akt pathway. PI3K phosphorylates PIP2 to 
generate PIP3 at the plasma membrane. Akt binds PIP3, allowing for phosphorylation and 
activation of Akt. Once active, Akt can phosphorylate XIAP to inhibit apopotosis and 
inactivate p21 and GSK3β by phosphorylation to increase cell cycle progression and 
energy consumption, respectively. Activating phosphorylations are shown in gold, while 
inhibitory phosphorylations are depicted in red. PTEN inhibits the activation of Akt by 





BAD by Akt prevents apoptosis while phosphorylation of the E3 ubiquitin ligase X 
linked inhibitor of apoptosis (XIAP) enhances the anti-apoptotic effects of XIAP (Dan et 
al., 2004; Datta et al., 1997). Inhibitory phosphorylation of glycogen synthase 3 beta 
(GSK3β) by Akt serves to increase energy consumption and attenuate the inhibitory 
effects of GSK3β on the oncogene β-catenin (Cross et al., 1995; Liu et al., 2002). Akt can 
also enhance cell cycle progression by enhancing cyclin D1 levels through inhibiting p21 
and p27 (Shin et al., 2002; Zhou et al., 2001).  
Activation of Akt in turn also enhances ΔNp63α levels, suggesting that Akt and 
ΔNp63α work in a positive feedback loop to jointly promote proliferation and survival 
(Segrelles et al., 2006). It remains unclear, however, as to how ΔNp63α is able to trigger 
the activation of Akt or how Akt stabilizes ΔNp63α.  
Canonical activation of Akt occurs through recruitment of Akt to the plasma 
membrane whereby it becomes phosphorylated at serines 308 and 473 by PDK1 and 
mTORC2, respectively (Sarbassov et al., 2005; Stokoe et al., 1997). Akt translocates to 
the plasma membrane by binding to phosphatidylinositol 3,4,5-trisphosphate (PIP3) via 
its pleckstrin homology domain (Burgering and Coffer, 1995; Franke et al., 1995). 
Phosphatidylinositol 3-kinases (PI3K) produce PIP3 by phosphorylating 
phosphatidylinositol 3,4-bisphosphate (PIP2) (reviewed in (Engelman et al., 2006). 
Gradients of PIP3, and thus Akt activation, are normally kept in check by the dual 
protein-lipid phosphatase PTEN (phosphatase and tensin homolog deleted on 
chromosome ten). PTEN removes the 3’ position phosphate from PIP3, essentially 
quenching the signal required for the activation of Akt (Maehama and Dixon, 1998). 
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Germline mutations of PTEN lead to a spectrum of hyperproliferative disorders, 
often characterized by hamartomas and cancer development that exemplify the need for 
functional PTEN in growth regulation (Blumenthal and Dennis, 2008). At the 
transcriptional level PTEN is regulated by the p63 family members, p53 and p73. Both 
p53 and TAp73 induce PTEN to reduce proliferation and prevent cancers (Stambolic et 
al., 2001; Vella et al., 2009). ΔNp73, similar to the ΔNp63 isoforms in their ability to 
repress the TA isoforms, can repress transcription of PTEN to enhance proliferation in 
thyroid cancer cells (Vella et al., 2009). A canonical p53 responsive element in the pten 
promoter allows p53 to bind to and enhance transcription of PTEN (Stambolic et al., 
2001). Interestingly, p73 controls PTEN transcription through a response element 
separate from that of p53 in the pten promoter (Vella et al., 2009). Because of the 
similarities in the DNA binding domain of the p53 family members, and the presence of 
both a p53 and a p73 response element in the pten promoter, ΔNp63α could bind the pten 
promoter to reduce PTEN expression and promote Akt activation and proliferation 
(Ogawa et al., 2007; Yang et al., 1998). Moreover, it is known that ΔNp63α is 
overexpressed while PTEN is down regulated in SCC (Odar et al., 2012). 
G. Post-Translational Modification of PTEN. 
 In addition to being regulated at the transcriptional level, PTEN is subject to many 
post-translational modifications that control its stability, enzymatic activity and 
subcellular localization. Unmodified PTEN is a 403 amino acid protein comprised of a 
PIP2 binding module at the amino-terminus followed by the phosphatase domain, a large 








Figure 5: Schematic of common post-translational modifications of PTEN. The 
functional domains of PTEN are color coded as follows: PIP2 binding module (PBM) in 
blue, phosphatase domain in orange, C2 domain in green, PDZ binding motif in red. Sites 
of and types of common covalent modifications and the enzymes responsible are shown 




(Georgescu et al., 1999). While the C2 domain is thought to confer membrane targeting 
to PTEN it has also been shown to be involved in protein-protein interactions along with 
the PDZ binding motif (Georgescu et al., 1999; Georgescu et al., 2000; Shen et al., 2007).  
 The phosphatase activity of PTEN can be diminished by multiple types of post-
translational modifications. Enzymatic activity of PTEN can be directly squelched by 
oxidation of cysteine 124, the key to nucleophilic removal of phosphate groups, by a 
reactive oxygen species (ROS) (Cho et al., 2004; Ross et al., 2007).   Phosphorylation of 
a cluster of serine and threonine residues between positions 366-385 are also known to 
regulate the stability and activity of PTEN. When phosphorylated, the C-terminal tail 
bends back to create a “closed” conformation that inhibits the degradation of PTEN (Al-
Khouri et al., 2005; Georgescu et al., 1999; Maccario et al., 2007). This phosphorylation-
induced close conformation, while stabilizing the protein, can also inhibit the 
phosphatase activity of PTEN by up to 30% (Torres and Pulido, 2001). A myriad of 
kinases have been shown to phosphorylate PTEN at different regions, all leading to 
increased stability at the expense of phosphatase activity. Phosphorylation by casein 
kinase 2 (CK2) at serines 370 and 388 primes PTEN for phosphorylation by GSK3β (Al-
Khouri et al., 2005). Phosphorylation of the C2 domain by ROCK1 has been shown to be 
important in blocking chemotaxis by inhibiting the phosphatase activity of PTEN in 
macrophages exposed to chemoattractants (Vemula et al., 2010). 
Phosphorylation can also increase protein stability by affecting the deposition of 
other covalent modifications. Phosphorylation by Rak at serine 336 has been shown to 
prevent PTEN degradation by blocking the interaction and subsequent ubiquitination by 
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the E3 ligase neuronal precursor cell-expressed developmentally downregulated 4 
(NEDD4-1) (Wang et al., 2007; Yim et al., 2009).  
Poly-ubiquitination of PTEN at lysine 13, and more predominantly, at lysine 289 
can lead to proteasome mediated degradation of PTEN (Trotman et al., 2007). Several E3 
ubiquitin ligases, in addition to NEDD4-1, have been shown to regulate the stability of 
PTEN. Most of the ligases responsible for PTEN ubiquitination are part of the NEDD4 
family of Homologous to the E6-AP Carboxyl Terminus (HECT) E3 ubiquitin ligases. 
These include NEDD4-1, WW domain containing protein 2 (WWP2) and chaperone-
associated E3 ligase (CHIP) (Ahmed et al., 2012; Maddika et al., 2011; Wang et al., 
2007). The Really Interesting New Gene (RING) E3 ligase XIAP also down regulates 
PTEN stability via ubiquitination (Van Themsche et al., 2009). 
Addition of a single ubiquitin moiety to PTEN at lysines 13 and 289, termed 
mono-ubiquitination, serves as a nuclear translocation signal for PTEN rather than a 
destruction signal like poly-ubiquitination (Ahmed et al., 2012; Trotman et al., 2007; Van 
Themsche et al., 2009). Of the E3 ligases known to ubiquitinate PTEN, only NEDD4-1, 
XIAP and CHIP have been demonstrated to influence the import of PTEN into the 
nucleus (Ahmed et al., 2012; Trotman et al., 2007; Van Themsche et al., 2009). 
Interestingly, NEDD4-1 has also been demonstrated to target ΔNp63α for destruction and 
could theoretically sequester NEDD4-1 away from PTEN (Bakkers et al., 2005). ΔNp63α 
also positively regulates heat shock protein 70 (HSP70) and Akt, which are important in 
the recruitment and activation of CHIP and XIAP, respectively (Ahmed et al., 2012; Dan 
et al., 2004; Wu et al., 2005). By influencing the recruitment and/or function of NEDD4-
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1, XIAP or CHIP, ΔNp63α could indirectly control the ubiquitination of PTEN and 
thereby regulate the stability and subcellular localization of PTEN. 
H. Nuclear PTEN. 
Nuclear PTEN is predominantly found in arrested or differentiated cells while 
loss of nuclear PTEN is associated with melanoma progression (Gimm et al., 2000; Ginn-
Pease and Eng, 2003; Jacob et al., 2009; Whiteman et al., 2002). Thus it is of potential 
therapeutic interest to understand how PTEN translocates into the nucleus and what the 
natural abundance of PTEN is in the nuclei of skin cells.  
PTEN harbors a cytoplasmic localization sequence near the N-terminus that keeps 
the vast majority of the protein in the cytoplasm (Denning et al., 2007). However, 
multiple mechanisms, including mono-ubiquitination, have been demonstrated to regulate 
nuclear import of PTEN (Trotman et al., 2007). PTEN also contains four non-classical 
nuclear localization signals that can mediate its interaction with the major vault protein to 
facilitate nuclear import (Chung et al., 2005). Other studies suggest that PTEN may 
simply diffuse through the nuclear pore complex (Liu et al., 2005a). At only 47 
kilodaltons, PTEN is a small enough to pass through nuclear pores which typically 
restrict proteins larger than 60 kilodaltons (Boulikas, 1993; Peters, 1986). 
Retention of PTEN within nucleus is a balance between nuclear import and 
export. The subcellular distribution of PTEN has been demonstrated to be cell cycle 
dependent, which is consistent with the strongest observations of nuclear PTEN in G1 
arrested or quiescent cells (Ginn-Pease and Eng, 2003; Jacob et al., 2009; Liu et al., 
2007). PTEN is exported out of the nucleus upon activation of the PI3K/Akt pathway at 
the beginning of S-phase (Liu et al., 2007). Active Akt mediates the nuclear export of 
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PTEN by leading to the downstream activation of S6K1 and S6K2 that then physically 
bind and shuttle PTEN out of the nucleus (Liu et al., 2007). The nuclear export of PTEN 
by S6 kinases can be blocked by the activation of LKB1 and AMPK upon stress signaling 
(Liu et al., 2011a).  
Once in the nucleus PTEN appears to have many functions independent of those 
associated with its cytoplasmic localization. Nuclear PTEN is important for inducing cell 
cycle arrest and maintaining chromosome stability and these processes may be, at least in 
part, independent of its phosphatase activity and thus of Akt inhibition (Chung and Eng, 
2005; Gimm et al., 2000; Jacob et al., 2009; Liu et al., 2005b; Liu et al., 2011b; Shen et 
al., 2007). Direct physical interaction of PTEN, regardless of the enzymatic ability of 
PTEN, has been shown to enhance the growth regulatory processes of multiple proteins. 
PTEN can shield p53 and p73 from MDM2 mediated degradation thereby enhancing 
induction of apoptotic genes (Lehman et al., 2011; Mayo et al., 2002). Nuclear PTEN has 
also been implicated in maintaining chromosome stability through co-localization with 
p73 and Rad51 at sites of DNA damage and through aiding in proper kinetochore 
attachment via CENP-C (Gupta et al., 2009; Lehman et al., 2011; Shen et al., 2007).   
I. Centrosome Associated Functions of PTEN. 
Loss of PTEN is associated with increased growth rates, invasion, chromosomal 
instability and aneuploidy (Ehlers et al., 2008; Levine et al., 1998; Li et al., 2009; Puc et 
al., 2005). PTEN contributes to genomic integrity by enhancing kinetochore attachment 
and Rad51 activity, but may also do so by regulating the mitotic machinery (Gupta et al., 
2009; Shen et al., 2007). PTEN null mouse embryonic fibroblasts (MEFs) escape taxol 
induced mitotic arrest faster than wildtype cells, suggesting that PTEN is involved in the 
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mitotic spindle checkpoint (Gupta et al., 2009). Constitutive pro-growth signaling, via 
Akt activation, was shown to display high levels of chromosome instability and 
centrosomal amplification that could be reversed by overexpression of PTEN (Li et al., 
2009; Nam et al., 2010). Basal Akt activity, and therefore PTEN status, has also been 
shown to be important in normal mitotic progression as pharmacologic inhibition of Akt 
resulted in centrosome defects and bi-polar spindle formation (Liu et al., 2008).  
Defective centrosome amplification (i.e. more than two centrosomes per cell) is 
frequently seen in both solid and hematological human cancers, while it rarely occurs in 
normal cells (Chng et al., 2006; Pihan et al., 2003). Previous studies indicate centrosome 
amplification may even be a causative agent in tumorigenesis (Chng et al., 2006; Pihan et 
al., 2003). Centrosomes are commonly called the microtubule-organizing complex and 
are comprised of two orthogonally arranged centrioles surrounded by a dense lattice of 
proteins constituting the peri-centriolar material (PCM). The recruitment of γ-tubulin to 
the heart of the proximal ends of centrioles is critical for centrosome maturation, 
formation of a bipolar spindle and successful progression through mitosis (Fuller et al., 
1995; O'Toole et al., 2012).  
Organization and maturation of centrosomes is a complex and dynamic process 
that involves numerous proteins, many of which are regulated in a cell cycle dependent 
manner. For instance, recruitment of γ-tubulin to mitotic centrosomes requires the 
phosphorylation of pericentrin (PCNT) by polo-like kinase 1 (PLK-1) (Haren et al., 2009; 
Lee and Rhee, 2011). Gamma-tubulin then feeds back into the development of mature 
centrosomes, in part, by enhancing the recruitment of other PCM proteins, including 
PLK-1 (Lee and Rhee, 2011). PTEN has previously been shown to influence PLK-1 
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degradation in a phosphatase independent manner by binding to the anaphase promoting 
complex (APC) and enhancing the targeting of PLK-1 for destruction (Song et al., 2011). 
Through the regulation of PLK-1, PTEN may be able to influence the recruitment of 
other centrosome associated proteins. In fact, aberrant PTEN expression is correlated 
with up-regulation of many centrosome associated proteins in endometrial cancers 
(Matsushima-Nishiu et al., 2001) as well as poor prognosis in breast cancers (Saal et al., 
2007). Together, this suggests that a balance between PTEN and Akt plays a key role 
centrosome function. 
J. Rationale and Hypothesis. 
PTEN is the second most commonly lost or mutated tumor suppressor in all of 
human cancers (Hollander et al., 2011). Loss of PTEN is associated with increased 
growth rates, invasion, chromosome instability and aneuploidy (Levine et al., 1998; Puc 
et al., 2005). Determining the mechanisms by which PTEN is regulated will contribute to 
understanding how PTEN can play an instrumental role in so many vital processes. PTEN 
is under the transcriptional control of p63 family members p53 and p73 (Stambolic et al., 
2001; Vella et al., 2009). The ability of the p53 family to share responsive elements, 
allows for the possibility that ΔNp63α may also transcriptionally regulate PTEN (Osada 
et al., 2005). Furthermore, ΔNp63α and PTEN both regulate cell proliferation by 
mediating the activity of Akt; PTEN  down regulates growth by inhibiting Akt (Maehama 
and Dixon, 1998; Stambolic et al., 1998) activation while ΔNp63α stimulates growth by 
enhancing Akt activation (Ogawa et al., 2007). ΔNp63α levels are also enhanced by 
activation of Akt, suggesting that ΔNp63α, PTEN, and Akt form a critical regulatory loop 
to control keratinocyte proliferation (Segrelles et al., 2006). 
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 ΔNp63α may further control keratinocyte proliferation by influencing the 
ubiquitination and subcellular distribution of PTEN. By influencing the recruitment 
and/or function of NEDD4-1, XIAP or CHIP ΔNp63α could indirectly control the 
ubiquitination of PTEN and thereby regulate the stability and subcellular localization of 
PTEN. The ability of ΔNp63α to modulate the subcellular localization of PTEN may also 
affect mitotic progression. ΔNp63α and Akt are essential for proper progression through 
mitosis and this may be accomplished via regulation of PTEN (Hau et al., 2011; Liu et 
al., 2008). 
The work detailed in this dissertation will test the hypothesis that ΔNp63α 
controls keratinocyte proliferation by inhibiting the expression, ubiquitination and 
subcellular translocation of PTEN. This study will determine if ΔNp63α is capable of 
controlling global PTEN expression, thereby forming a critical regulatory loop with Akt 
to maintain normal cellular proliferation. Secondly, it will also establish whether the 
ΔNp63α/PTEN axis is clinically relevant by studying the expression of ΔNp63α and 
PTEN in human NMSC. Finally, the work presented in this dissertation will also 
demonstrate an essential and novel role for PTEN and Akt in regulating the mitotic 
machinery. Together this dissertation will increase the understanding of how ΔNp63α 
contributes to increased cell proliferation and how loss of PTEN plays a multi-faceted 







A. Cell Lines, Reagents and Plasmids. 
H1299, PC3 and A431 were purchased from American Type Culture Collection 
(ATCC) while HaCaT cells were obtained from Dr. Dori Germolec (National Institute of 
Environmental Health Sciences). Dr. Elsa Flores (University of Texas M.D. Anderson 
Cancer Center, Houston, TX) generously gifted primary and E1A transformed wildtype 
and p63 null mouse embryonic fibroblasts (MEF). All cell lines except primary 
keratinocytes were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 8% fetal bovine serum and 100 U/mL of penicillin/streptomycin and 
maintained at 37° C in 5% CO2. Adult primary human keratinocytes (HEK) were 
maintained in Epilife media supplemented with human keratinocyte growth serum and 
100 U/mL of penicillin and streptomycin and 0.25 μg/mL amphotericin B (Cascade 
Biologics, Portland, OR). Neonatal human primary keratinocytes (NHEK) were 
maintained in KGM-Gold media supplemented with BPE, 2 mL bovine pituitary extract, 
0.5 mL human epidermal growth factor, 0.5 mL insulin, 0.5 mL hydrocortisone, 0.5 mL 
transferrin, 0.25 mL epinephrine and 0.5 mL gentamycin according to manufacturer’s 
protocol (Lonza Walkersville, Walkersville, MD). The Akt specific inhibitor MK2206 
was dissolved in dimethyl sulfoxide (DMSO) and used at a final concentration of 10 μM 
for all experiments (Selleckchem, Houston, TX).  
The expression plasmid encoding murine ΔNp63α in the pcDNA3.1A backbone 
was kindly provided by Dr. Frank McKeon (Harvard Medical School, Boston, MA). 
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Human hemagglutinin (HA) tagged ΔNp63α was donated by Dr. Subham Basu (Barts 
and The London School of Medicine and Dentistry, London, UK). Constitutively active 
myristol-Akt (CA-Akt) and kinase dead Akt were donated by Dr. Lindsey D. Mayo 
(Indiana University, Indianapolis, IN). Dr. Steven Berberich (Wright State University, 
Dayton, OH) kindly donated the 6x-His tagged ubiquitin (His-Ub) expression plasmid 
while the HA-ubiquitin and human wild-type NEDD4-1 expression plasmids were 
graciously provided by Dr. Miguel Martins (University of Leicester, Leicester, UK).  
The full length PTEN-luc reporter used was described previously (Virolle et al., 
2001). Four minimal PTEN luciferase reporters (designated A-C, E) were created by 
annealing primers to the regions of interest followed by ligation into the pGL3 Basic 
promoter-less luciferase reporter (Promega, Madison, WI) at the KPNI and HINDIII sites 
with T4 ligase (New England Bioscience, Ipswich, MA) for 2 hours at room temperature. 
The sequence of primers used can be found in Table 1 located in the methods appendix. 
B. Transient Transfections. 
For plasmid transfections cells were transfected at 80% confluence using 
Lipofectamine 2000 in antibiotic free DMEM (Life Technologies, Grand Island, NY). 
Cells were processed for downstream analysis 24 hours post transfection. Knockdown 
studies were conducted by two rounds of Oligofectamine or Lipofectamine RNAiMax 
based transfections carried out 24 hours apart (Life Technologies). All siRNAs and the 
Allstars Non-Silencing Control (NSC) were purchased from Qiagen (Valencia, CA). The 
target sequences for the siRNAs can be found in Table 2 of the methods appendix.  
C. Real Time PCR. 
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Total RNA from cells was extracted using the E.Z.N.A RNA isolation kit (Omega 
Bio-Tek, Norcross, GA) as per manufacturer's protocol. A total of 1 μg RNA was used to 
synthesize cDNA by using TaqMan reverse transcription kit (Applied Biosystems, Foster 
City, CA). TaqMan based real-time PCR analysis was performed on ABI Prism7900HT 
sequence detection system using TaqMan Gene Expression Master mix and gene-specific 
assays on demand (AOD) for genes of interest and normalized to endogenous GAPDH 
for human genes or to β-actin for murine genes of interest (PE Applied Biosystems, 
Foster City, CA). Human AODs used were GAPDH (4325792), VDR (Hs_0017213_m1), 
p63 (Hs_00978340_m1), ΔNp63 (Hs_00978339_m1), TAp63 (Hs_00186613_m1), 
TAp73 (Hs_01056228_m1), ΔNp73 (Hs_1065727) IGFBP-3 (Hs_00426287_m1), PTEN 
(Hs_00829813_s1), and NEDD4-1 (Hs_0040645_m1). Murine AODs were p63 
(Mm00495788_m1), PTEN (Mm00477210_m1) and β-actin (Mm00607939_s1). Fold 
change in genes of interest, relative to endogenous loading controls, was calculated using 
the comparative ΔΔCT method on SDS2.2.2 software (Pfaffl, 2001). 
D. Immunoblot analysis. 
 Whole cell lysates were prepared by lysing the cells in phosphatase inhibitor 
containing buffer (50 mM Tris-HCl pH 8, 120 mM NaCl, 5 mM NaPPi, 10 mM NaF, 30 
mM paranitrophenylphosphate, 1 mM benzamidine, 0.1% NP-40, 1 % Triton X-100 and 
0.2 mM PMSF, 100 nM sodium orthovanadate) supplemented with protease inhibitors. 
Subcellular fractionations were carried out using the NE-PER kit as per manufacturer’s 
instructions (Pierce, Rockford, IL). Total protein amounts were measured using BCA 
(Pierce, Rockford, IL) protein detection method and equivalent amounts of protein 
extracts were mixed with an appropriate volume of 10x loading dye (0.5 M dithiothreitol, 
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0.3 M Tris pH 6.8, 10% SDS, 50% glycerol and 0.05% bromophenol blue) and separated 
by 10% SDS-PAGE, or 7.5% SDS-PAGE for ubiquitinated proteins. Following 
separation by PAGE, proteins were transferred onto polyvinylidene difluoride membranes 
and blocked with 5% milk in Tris buffered saline with 0.5% Ttween (TBST) or 1% BSA 
in TBST for detection of phosphorylated proteins. Membranes were subsequently 
immunoblotted for specific proteins as follows: anti-p63 (4A4), anti-p63α (H-129), anti-
β-actin (AC-15), anti-α-tubulin (B-7, normal mouse IgG (sc-2025), normal rabbit IgG 
(sc-2027) (Santa Cruz Biotechnologies, Santa Cruz, CA); anti-pAkt (S473) #9271, anti-
Akt #9272, anti-PTEN #9559, anti-NEDD4 #3607, anti-p-S6 #4838, anti-S6 #2217, anti-
PARP #9542 (Cell Signaling, Boston, MA). Anti-Lamin A/C (BD Biosciences #612162) 
was donated by Dr. Steven Berberich (Wright State University) while the ΔNp63 specific 
RR14 antibody was gifted by Dr. Satrijit Sinha (SUNY-Buffalo). Antibodies specific to 
total p73 (IMG-259A) and ΔNp73 (IMG-313A) were purchased from Imgenex (Imgenex, 
San Diego, CA). Appropriate horseradish peroxidase-conjugated secondary antibodies 
(Promega) were used for chemiluminescence detection with Western Lightening Pro 
Chemiluminescent Substrate kit (Perkin-Elmer, Waltham, MA) and imaged with a 
Fujifilm Las3000 and Multi-Gauge Software (GE Healthcare-Fujifilm, Pittsburgh, PA).  
E. Immunofluorescence analysis. 
Cells were plated onto sterile, acid washed glass coverslips at least 24 hours prior 
to treatment. Cells were fixed with 2% paraformaldehyde for 15 minutes at room 
temperature. Coverslips were washed thrice to remove excess paraformaldehyde prior to 
permeabilization with 0.2% Triton X-100 diluted in PBS for 5 minutes. Cells were 
simultaneously washed and blocked by three 5 minute washes with 0.5% normal goat 
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serum in PBS (NGS-PBS). Proteins of interest were detected by incubating coverslips 
with the designated antibody diluted in 0.5% NGS-PBS for 1 hour at room temperature in 
a humid chamber. Excess primary antibody was removed by three consecutive washes 
with NGS-PBS followed by incubation with isotype appropriate AlexaFluor-488 or 
AlexaFluor-568 conjugated secondary antibodies for 1 hour. Coverslips were mounted 
onto glass slides and nuclei counterstained using VectaShield + DAPI (4',6-diamidino-2-
phenylindole) Mounting Medium (Vector Laboratories, Burlingame, CA). p63 was 
visualized with rabbit anti-p63α H-129 (diluted 1:50 in NGS-PBS, Santa Cruz). PTEN 
was detected with mouse monoclonal anti-PTEN 6H2.1 antibody in NGS-PBS (1:50 
dilution from Cascade Bioscience, Winchester, MA). Confirmation of PTEN subcellular 
localization by immunofluorescence was also made using rabbit monoclonal anti-PTEN 
(#9559) at a dilution of 1:25 (Cell Signaling, Boston, MA). Gamma tubulin was detected 
with rabbit polyclonal anti-γ-tubulin at dilution of 1:2000 (DQ-19, Sigma-Aldrich). 
Rabbit polyclonal PLK-1 and Pericentrin were detected at 1 μg/mL, while ninein 
(ab4447) was detected at 20 μg/mL (AbCam, Cambridge, MA).  
Formalin fixed, paraffin-embedded embryonic mouse sections used for 
immunofluorescence in Figures 3, 25B and 36 were a kind gift from Dr. Satrajit Sinha 
(SUNY Buffalo). All experimental procedures involving mice were approved by the 
Institutional Animal Care and Use Committee of the State University of New York at 
Buffalo. Human tissue samples were obtained and handled in full approval and 
accordance with Wright State University Institutional Review Board protocols. Human 
skin microarray (SK805, Biomax, Rockville, MD) and paraffin embedded embryonic 
mouse sections were first treated to four, 10 minute incubations at room temperature in 
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HistoClear (National Diagnostics, Atlanta, GA) with gentle agitation to remove the 
paraffin. The tissues were re-hydrated by 5 minute washes in gradient ethanol (95%, 
70%, 50%) followed by distilled water for 5 minutes. A heat based antigen retrieval 
technique was used to unmask p63 and PTEN epitopes by immersing slides in 
Tris/EDTA buffer (10 mM Tris Base, 1 mM EDTA Solution, 0.05% Tween 20, pH 9.0) 
and heating in a pressure cooker at 90°C for 12 minutes. Slides were cooled to room 
temperature before blocking for 3 hours in 5% normal goat serum in PBS plus 0.5% 
Tween 20. Tissues were incubated in primary antibodies, mouse p63 4A4 (Santa Cruz) 
and rabbit PTEN #9559 (Cell Signaling) diluted 1:25 in blocking buffer, overnight at 
4°C. Excess primary antibody was removed by three consecutive washes with NGS-PBS 
followed by incubation with isotype appropriate AlexaFluor-488 or AlexaFluor-568 
conjugated secondary antibodies for 1 hour. Coverslips were mounted onto tissues slides 
and nuclei counterstained using VectaShield + DAPI Mounting Medium (Vector 
Laboratories). 
Images were acquired using a Leica DMI6000 B (Leica Microsystems, Wetzlar, 
Germany) inverted epifluorescent microscope and ImagePro 6.2 Software (Media 
Cybernetics, Bethesda, MD). Analysis of mean fluorescent intensity (MFI) was done as 
previously described (Lee and Rhee, 2011). Briefly, the fluorescence intensity within the 
region of interest was defined by drawing a circle around the centrosome using ImagePro 
6.2 (Media Cybernetics). The background intensity from an identically sized circle 
adjacent to the area of interest was subtracted from the MFI of the area of interest. At 
least 5 measurements of each protein were taken of each sample for studies of paraffin 
embedded tissues while centrosome studies measured at least 25 centrosomes per 
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condition for each experiment with an n = 3 independent experiments. Statistical 
significance of differences was determined by Student’s t-test for all centrosome related 
experiments. Significance for MFI in human epidermal samples was determined by one-
way ANOVA with a Bonferroni ad-hoc test and the Pearson Product Moment analysis 
was used to determine correlations between p63 and PTEN. A probability value of < 0.05 
was considered statistically significant. 
 F. Chromatin Immunoprecipitation. 
Chromatin Immunoprecipitation (ChIP) was done using the ChIP-IT Express Kit 
as per manufacturer’s protocol (Active Motif, Carlsbad, CA) and as described previously 
(Kommagani et al., 2009). Briefly, asynchronously growing HaCaT and A431 cells were 
fixed with 2.7% formaldehyde in minimal media for 10 minutes with gentle agitation. 
Fixation was stopped with ice cold 1x Glycine Stop solution for 5 minutes at room 
temperature with gentle agitation. Cells were scrapped off culture dishes using cold PBS 
supplemented with PMSF and pelleted by centrifugation for 10 minutes at 1257x g at 
4°C. Pellets were resuspended in 1 mL of ice cold lysis buffer supplemented with 5 μL 
protease inhibitor cocktail (PIC) and 5 μL PMSF. Cells were lysed by 10 strokes in an ice 
cold dounce homogenizer and nuclei were subsequently pelleted by centrifugation for 10 
minutes at 2350x g at 4C. Nuclei were resuspended in the provided shearing buffer 
supplemented with PIC and PMSF. A431 chromatin was sonicated on ice using a Fisher 
Scientific model 500 sonic dismembrator for pulses lasting for 59 sec with 10 sec resting 
in between pulses. HaCaT chromatin was sonicated for 3 total cycles of 30 sec pulses 
with 10 sec resting in between. Fragmentation of chromatin to sizes of 300-1,000 base 
pairs, the majority which being 300-500 base pairs, was confirmed by electrophoresis on 
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a 1% agarose gel after de-proteinization with proteinase K for for 2 hours at 42°C.  A 
total of 16 μg of sheared chromatin was pre-cleared with Protein G magnetic beads for 2 
hours at 4°C before immunoprecipitation overnight at 4°C with 2 μg of IgG control, anti-
p63 4A4, anti-63α, or anti-p53 AB-6 diluted in 25 μL of Protein G magnetic beads, 20 μL 
of ChIP buffer 1, and 2 μL PIC. A portion (10%) of sheared chromatin that was not 
subjected to immunoprecipitation was used as input DNA. Chromatin was eluted from 
antibody-Protein G complex by three 15 minute incubations in 50 μL ChIP elution buffer 
(1M NaHCO3, 1% SDS) at room temperature. 
Input and immunoprecipitated chromatin were reverse cross linked by incubating 
chromatin in 5 M NaCl with RNase A overnight at 65°C. Any remaining protein was 
digested by proteinase K treatment for 2 hours at 42°C. Final DNA was cleaned using the 
QiaQuick PCR Purification Kit (Qiagen) before PCR amplification with GoTaq Green 
Master Mix (Promega, Madison,WI). Sequences for primers can be found in Table 3 of 
the methods appendix. Primers for the p21 promoter were as described previously 
(Kommagani et al., 2009). PCR conditions used are as follows, a total of 40 cycles were 
performed each consisting 30 sec at 94
0 
C, 30 sec at 55
0
C and 30 sec at 68
0 
C. 
G. Cell Proliferation. 
Cells harvested after the second round of siRNA transfection were re-seeded at 2 
x 10
4
 cells/well in a 6 well plate for colony formation assays. At 72 hours post re-seeding, 
cells were stained with 1% crystal violet. Twenty random images were taken per 
condition and colony number and area from each frame was measured using ImagePro 
6.2 Software (Media Cybernetics). For cell growth assays, cells were re-seeded at 5,000 
cells/well in 96 well plates MTS assays or at 10,000 cells/well in 12 well plates for trypan 
39 
 
blue exclusion assays after 24 hours from the second round of siRNA transfection. The 
MTS assay was performed as per manufacturer’s instructions at days indicated 
(Promega). Cell proliferation as measured by trypan blue exclusion was done in triplicate 
per condition per day post siRNA transfection. 
H. Dual Luciferase Assay. 
Cells were transfected with 100 ng of either a luciferase reporter with the full 
length pten promoter (PTEN-luc) or the designated minimal pten promoter reporter along 
with the ΔNp63α or empty vector. To control for transfection efficiency cells were also 
transected with 5 ng Renilla luciferase expression vector. Dual-luciferase assays were 
performed using Dual-Luciferase Reporter 1,000 Assay System as per manufacturer’s 
protocol (Promega, Madison, WI). The luciferase activity of the experimental reporter 
was normalized to Renilla luciferase activity as measured in relative light units (RLU). 
The effect of ΔNp63α overexpression on each experimental reporter is further reported as 
change RLU values as compared to vector transfected cells.  
I. Ubiquitination Assays. 
 H1299 cells were transfected with the indicated expression plasmids and either 
HA-ubiquitin or His-Ub. For experiments using HA-Ub, H1299 cells were lysed in a high 
salt buffer (300 mM NaCl, 100 mM Tris pH 8, 0.2 mM EDTA, 0.1% NP40, 10% 
glycerol). A total of 1 mg protein was diluted to a final concentration of 100 mM NaCl 
with a salt free buffer (100 mM Tris pH 8, 0.2 mM EDTA, 0.1% NP40, 10% glycerol); 
10% of the total protein was saved for input control. Protein lysates were pre-cleared with 
20 μl of magnetic Protein G Dynabeads (Life Technologies) for 1 hour followed by 
overnight incubation at 4°C with 1 μg anti-hemagglutinin (clone 12CA5) donated by Dr. 
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Patrick Dennis. Antibody-ubiquitinated protein complexes were pulled out of solution 
with Protein G Dynabeads (Life Technologies) by an additional 2 hours incubation at 
4°C. The isolated beads were resuspended in 70 μL 100 mM NaCl buffer (100 mM NaCl, 
100 mM Tris pH 8, 0.2 mM EDTA, 0.1% NP40, 10% glycerol) and resolved by 
immunoblot analysis as described above. 
Ubiquitination assays with the His-Ub expression plasmid were completed as 
described previously (Jaffray and Hay, 2006). Briefly, 24 hours post transfection with 
His-Ub expression plasmid, cells were pelleted and 20% of the pelleted cells were lysed 
in phosphatase inhibitor containing buffer (PhIB) for determination of protein 
concentration and saved for the input control. The remaining 80% of the cells were lysed 
in guanidinium-HCl buffer (6 M guanidinium-HCl, 0.1 M Na2HPO4/NaH2PO4, pH 8, 
0.01 M Tris HCl, 10 mM β-mercaptoethanol, 5 mM imidazole). Equivalent amounts of 
total protein in 6 M guanidinium HCl buffer (1 mg), as determined by BCA analysis of 
the fraction lysed in PhIB, were rotated overnight with 75 μl Nickle-NTA beads (Qiagen) 
at 4°C.  The beads were pelleted by centrifugation at 2350x g for 5 minutes at 4°C. Beads 
were successively washed for 15 minutes each at room temperature in the following 
buffers: Wash Buffer 1 (6 M guanidinium-HCl, 0.1 M Na2HPO4/NaH2PO4, pH 8, 0.01 M 
Tris HCl, 10 mM β-mercaptoethanol), wash buffer 2 (8 M urea, 0.1 M 
Na2HPO4/NaH2PO4, 0.01 M Tris HCl, 10 mM β-mercaptoethanol), wash buffer 3 (8 M 
urea, 0.1 M Na2HPO4/NaH2PO4, pH 6.3, 0.01 M Tris HCl, 10 mM β-mercaptoethanol, 
0.2% Triton X-100), wash buffer 4 (8 M urea, 0.1 M Na2HPO4/NaH2PO4, pH 6.3, 0.01 M 
Tris HCl, 10 mM β-mercaptoethanol, 0.1% Triton X-100), and wash buffer 5 (8 M urea, 
0.1 M Na2HPO4/NaH2PO4, pH 6.3, 0.01 M Tris HCl, 10 mM β-mercaptoethanol). His-
41 
 
ubiquitinated proteins were eluted off of the washed beads by 30 minute incubation at 
room temperature in 100 μL elution buffer (200 mM imidazole, 0.15 M Tris-HCl, pH 6.7, 
30% glycerol, 0.72 M β-mercaptoethanol, 5% SDS). Input control and eluted His-Ub 
proteins were processed for immunoblot analysis as described above. 
I. Methods Appendix. 
 
Table 1: Primers used for generation of minimal luciferase reporters 
Primer  Sequence (5’ to 3’) 







C for CGAGCAAGCCCCAGGCAGCTACACTGGGCATGCTCA 






Table 2: Target sequences for siRNA 









Table 3: Primers used for chromatin immunoprecipitation 
Primer  Sequence (5’ to 3’) 
A forward CGGGGTACCCGTCCCACTCACAGGGATCCTCT 
A reverse CCCAAGCTTCTGCTATTGTGTCGCCAGCGTCT 
B forward CCCTGCATTTCCTCTACA 
B reverse GAGGCGAGGATAACGAGCTA 
C forward GCACCCATCTCAGCTTTCAT 
C reverse CAAGCCGCAGGCTCTACT 
D forward GACTGCGCTCAGTTCTCTCC 
D reverse AGAGGCTGCACGGTTAGAAA 
E forward CGGGGGTACCAGCGGCGGCGTTTCTCGCCTCCT 







A. p63 negatively regulates PTEN expression. 
To examine how p63 controls cell proliferation in vitro, several keratinocyte-
derived cell lines were employed. Primary Human Epidermal Keratinocytes (HEKs) were 
used to whenever possible. Because of the difficulty growing, limited lifespan and culture 
costs associated with HEKs, transformed keratinocyte cell lines were used for the 
majority of the experiments within this dissertation. A431 cells, originating from a 
cutaneous squamous cell carcinoma of the vulva, were used as a model for atypical 
cancerous keratinocytes while the spontaneously transformed, non-tumorigenic HaCaT 
cell line was used to model relatively normal human keratinocytes.  
Due to the often opposing functions of the TAp63 and ΔNp63 isoforms, the 
predominant p63 isoforms in any cell line must first be identified in order to determine 
how p63 influences keratinocyte proliferation. Consistent with earlier reports, ΔNp63α 
was found to be the predominant p63 isoform in both these cell lines (Di Como et al., 
2002; Mangiulli et al., 2009; Megyeri et al., 2009). Quantitative real time PCR (qRT-
PCR) analysis with TAp63 and ΔNp63 specific primers demonstrated that ΔNp63 mRNA 
levels were several orders of magnitude higher than TAp63 mRNA levels in A431, 
HaCaT, and HEK cells when compared to the p63 null, non-small cell lung carcinoma 
H1299 cell line (Figure 6A). Endogenous TAp63 transcript levels were frequently near 
the limit of detection, indicating very low expression of the TAp63 isoforms during 







Figure 6: ΔNp63α is the predominant isoform in keratinocyte cell lines. (A) RT-PCR 
analysis of total cDNA from the indicated cell lines using primers specific to TA or 
ΔNp63 isoforms. H1299 cells lacking p63 were used as a negative control. (B) 
Immunoblot analysis using pan-p63 (4A4), ΔNp63 specific (RR14), and p63α isoform 




In order to determine the predominant C-terminal splice variants of p63 present in 
A431 and HaCaT cells, whole cell lysates were subjected to Western blot analysis 
alongside extracts from H1299 cells overexpressing each of the six main isoforms of p63 
as positive controls. A distinct band of ~70 kDa was observed in both A431 and HaCaT 
lysates when probed with an antibody detecting all isoforms of p63 (4A4) (Figure 6B). 
This band migrated identically to that of the ΔNp63α control and showed similar 
intensities when probed with the pan-p63 and ΔNp63 specific antibodies. Occasionally, 
bands smaller than the main 70 kDa band were observed in lysates from either A431 or 
HaCaT cells. Because of the unreliable presence of these bands as well as their detection 
in H1299 cells with forced expression of a single p63 isoform, they were determined to 
be degradation products of ΔNp63α rather than bands corresponding to ΔNp63β or 
ΔNp63γ. No higher molecular weight bands in A431 or HaCaT lysates were observed 
with either the pan-p63 or TAp63 specific antibodies, demonstrating the lack of 
endogenous TAp63 protein in actively growing keratinocyte cultures. The inability to 
detect endogenous TAp63 protein along with the molecular weight and use of isoform 
specific antibodies confirms ΔNp63α as the predominant p63 isoform in both A431 and 
HaCaT cells.  
Having determined that ΔNp63α is the predominant isoform, and only detectable 
p63 protein in keratinocyte cell lines, the effects of ΔNp63α on PTEN expression were 
next determined. Using multiple pan-p63 siRNAs, p63 expression was knocked down in 
A431 (Figure 7A), HaCaT cells (Figure 7B), and adult HEKs (Figure 7C). Silencing p63 
led to a modest, but consistent increase in PTEN transcript levels in all cell lines with all 
siRNAs tested. Increased IGFBP-3 levels, previously shown to be negatively regulated 
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by ΔNp63α served as a positive control (Barbieri et al., 2005). The increase in PTEN 
transcript levels upon silencing of p63 correlated with increased protein levels compared 
to non-silencing control (NSC) transfected cells (Figure 7A-C, lower panels). We also 
confirmed that the pan-p63 siRNAs equally knockdown TAp63 and ΔNp63 (Figure 8A). 
To demonstrate that the increased PTEN expression observed upon p63 silencing is due 
to ΔNp63α we knocked down ΔNp63α expression using a ΔNp63 specific siRNA and 
showed that loss of only ΔNp63α, the predominant isoform, still led to an increase in 
PTEN mRNA (Figure 8B). Although the corresponding increase in PTEN protein levels 
in Figure 7 seems modest, minute changes in PTEN protein levels have been shown to 
have profound biological impact and thus the modest increases in PTEN observed upon 
p63 knockdown were considered biologically significant (Alimonti et al., 2010).  
Mouse embryonic fibroblasts (MEFs) from p63-/- and wild type mice were 
utilized to confirm that increased PTEN expression upon loss of p63 was not an artifact. 
PTEN transcript and protein levels were found to be elevated in both E1A transformed 
MEFs (Figure 9A) as well primary MEFs obtained from p63-/- mice when compared to 
those of wild type mice (Figure 9B). A minor amount of residual p63 mRNA was 
detectable in the p63-/- MEFs due to the location of primers used for qRT-PCR spanning 
between exons 4 and 5 while the p63 protein was rendered nonfunctional due to the 
deletion of exons 6-8 in the Trp63 gene (Yang et al., 1999). The residual p63 mRNA fails 
to generate any p63 proteins and is barely within the limit of detection by qRT-PCR. The 
increase in PTEN mRNA and protein in p63-/- MEFs was very similar to the increases 
observed from p63 knockdown in keratinocyte cell lines (Figure 7), consistent with 








Figure 7: p63 negatively regulates PTEN expression in keratinocyte cell lines. (A) 
A431, (B) HaCaT cells and (C) Primary adult human epidermal keratinocytes (HEKa) 
were transfected with non-silencing control (NSC) siRNA or siRNAs targeting all 
isoforms of p63. Total RNA was extracted and transcript levels of p63, PTEN and 
IGFBP-3 were analyzed by qRT-PCR. Y-axis represents the change in PTEN and p63 
transcript levels relative to NSC transfected cells. Representative immunoblots of p63 
and PTEN are shown in the bottom panels. Fold change in protein, after normalization to 




It has been demonstrated that PTEN is regulated at the transcriptional level by the 
p63 family members p53 and p73 (Stambolic et al., 2001; Vella et al., 2009). Because 
ΔNp63α can act in a dominant negative manner to prevent the pro-apoptotic 
transcriptional activities of other p53 familiy members (Yang et al., 1998), the 
involvement of the various p53 family members on regulation of PTEN by ΔNp63α was 
investigated. Both A431 and HaCaT cells harbor mutations in p53 that disrupt the normal 
binding pattern of p53 and abrogate the tumor suppressive functions of p53 (Park et al., 
1994; Rolley et al., 1995). Loss of ΔNp63α resulted in increased PTEN expression in 
cells harboring mutant p53 (Figure 7A-B) as well as in primary keratinocytes (Figure 7C) 
and MEFs (Figure 9B) expressing wild type p53, demonstrating that repression of PTEN 
expression by p63 is independent of p53. 
In order to rule out the possibility that the induction of PTEN observed after 
silencing ΔNp63α was not simply caused by alleviation of the dominant negative effects 
of ΔNp63α on either the TAp73 or TAp63 isoforms, the expression of p73 in 
keratinocytes first had to be examined. The levels of both TA and ΔN isoforms of p73 
were examined by qRT-PCR and immunoblot analyses (Figure 10). As shown in Figure 
10A, ΔNp73 was the predominant isoform of p73 observed in both A431 and HaCaT cell 
lines, suggesting that these cells may have a deficient p73-dependant pro-apoptotic 
program since the ΔNp73 isoforms can act in a dominant negative manner toward the 
TAp73 isoforms similar to the relationship of ΔNp63/TAp63 proteins. TAp73α and 
TAp73β were, however, still detectable at the protein level and could therefore influence 







Figure 8: Selective knockdown of ΔNp63 increases PTEN expression. (A) HaCaT 
cells were transfected with NSC or siRNA against all isoforms of p63 or siRNA specific 
to either the ΔNp63 isoforms or TAp63 isoforms. Total RNA was extracted and analyzed 
by qRT-PCR. Y-axis represents the change in transcript levels relative to NSC 
transfected cells after normalization to GAPDH. (B) HaCaT cells were transfected with 
NSC or siRNA specific to the ΔNp63 isoforms. Total RNA and protein were extracted 
and analyzed as in (A) for ΔNp63α and PTEN levels. Y-axis represents the fold change in 
PTEN and ΔNp63 transcript levels relative to NSC transfected cells. Representative 
immunoblots of ΔNp63α and PTEN are shown in the bottom panels. Fold change in 
protein, after normalization to β-actin and relative to non-silencing control, is listed above 









Figure 9: Elevated PTEN expression in p63 null MEFs. Total RNA extracted from (A) 
E1A transformed and (B) primary mouse embryonic fibroblasts (MEF) obtained from 
wild-type and p63 null mice were subjected to qRT-PCR to detect transcript levels in the 
top panel. Bottom panel represents immunoblot analysis of whole cell extracts from wild-
type and p63 null MEFs; change in PTEN protein levels compared to wildtype MEFs is 
listed above each band. Note: p63 was undetectable at the protein level and near the limit 








Figure 10: ΔNp73β is the predominant p73 isoform in A431 and HaCaT cells. (A) 
qRT-PCR analysis of total cDNA from indicated cell lines using primers specific for the 
TA or ΔNp73 isoforms. (B) Immunoblot analysis using pan-p73 or ΔNp73 specific 




In order to rule out the possibility that silencing ΔNp63α was inducing PTEN 
expression by simply reversing its dominant negative effects on either the TAp73 or 
TAp63 to allow transcriptional up-regulation by TAp63 and/or TAp73, cells were 
transfected with non-silencing control siRNA or siRNA to ΔNp63α and/or siRNA 
specific to either TAp63 (Figure 11A) or TAp73 (Figure 11B). In A431 cells, which 
showed higher levels of TAp63 mRNA (Figure 6A), silencing ΔNp63α significantly 
inhibited ΔNp63α expression and increased PTEN mRNA similar to the use of pan-p63 
siRNAs in Figure 7A (Figure 11A). Interestingly, silencing TAp63 also led to an increase 
in PTEN transcript levels, however this may be the result of the minor reduction in 
ΔNp63 mRNA caused by silencing TAp63 (Figure 11A). Silencing both ΔNp63α as well 
as TAp63 isoforms also led to significant PTEN induction similar to silencing ΔNp63 
alone, therefore suggesting that PTEN induction observed upon silencing ΔNp63α occurs 
primarily independent of any effects on TAp63 activity. Immunoblot analysis results 
were consistent with the qRT-PCR results in that silencing ΔNp63 had more profound 
effects on PTEN protein than silencing TAp63 (Figure 11A, lower panel). Endogenous 
TAp63 protein could not be detected by immunoblot analysis (Figure 6B).  
Similarly to the effects on TAp63, silencing TAp73 alone in HaCaT cells did not 
significantly affect the PTEN expression when compared to non-silencing control (Figure 
11B). HaCaT cells were used since they expressed the highest amount of endogenous p73 
(Figure 10A). When both ΔNp63α and TAp73 were silenced together, the increase in 
PTEN expression was similar to the condition in which only ΔNp63α was silenced. 
Together our results demonstrate that up-regulation of PTEN upon ΔNp63α knockdown 







Figure 11: ΔNp63α is the predominant isoform responsible for changes in PTEN. 
(A) A431 cells were transfected with non-silencing control (NSC) siRNA, siRNA 
specific to the ΔNp63 or TAp63 isoforms, or both. Total RNA was extracted and changes 
transcript levels were analyzed by qRT-PCR. Y-axis represents the change in transcript in 
levels relative to NSC transfected cells after normalization to the endogenous loading 
control. Representative immunoblots for the indicated proteins are shown in the bottom 
panel. (B) HaCaT cells were transfected with non-silencing control (NSC) siRNA, 
siRNA specific to ΔNp63 or TAp73, or both. Total RNA was extracted and changes 
transcript levels were analyzed by qRT-PCR. Y-axis represents the change transcript 
levels relative to NSC transfected cells. Representative immunoblots for the indicated 
proteins are shown in the bottom panel. Fold change in protein, after normalization to β-




B. PTEN is a direct target of ΔNp63α.   
Loss of ΔNp63α led to increases in both PTEN transcript and protein levels, 
suggesting that PTEN may be a direct transcriptional target of p63. Examination of the 
pten promoter revealed the presence of several putative p63 responsive elements (REs) in 
addition to the p53 RE described previously (Figure 12A) (Stambolic et al., 2001). To 
define the region of the pten promoter to which ΔNp63α binds, chromatin 
immunoprecipitation (ChIP) assays were performed in A431 and HaCaT cells. ChIP 
analysis was performed using antibodies that recognize all p63 isoforms (4A4 antibody) 
or a p63 antibody that specifically recognizes only the p63α isoforms (H-129 antibody). 
Not surprisingly, p63 bound to the same locations of the pten promoter with similar 
affinities in both A431 and HaCaT cells. p63 bound to regions of the pten promoter with 
multiple p63 REs as seen when immunoprecipitated with either pan-p63 or alpha isoform 
specific antibodies (Regions A and B, Figure 12B). p63 also bound the p53 responsive 
element, which is consistent with previous reports demonstrating that p63 can to bind to 
promoters of other p53 targets (Region C, Figure 12B) (Westfall et al., 2003). Not all 
putative p63 responsive elements, however, showed binding of p63 at the pten promoter. 
Region D contained two half sites that matched the criteria for a p63 specific RE, yet 
failed to demonstrate binding. Interestingly, Region D corresponds to the region reported 
to be bound by p73 in thymic cells further confirming the results from Figure 11 that p63 
does not interfere with p73-mediated regulation of PTEN (Vella et al., 2009). Region E 
with a canonical p63 RE only showed strong binding when immunoprecipitated with the 







Figure 12: ΔNp63α binds the pten promoter. (A) Schematic of putative p63 binding 
sites and documented p53 binding sites in the pten promoter (Accession #AF067844). 
Each gray oval represents a single putative p63 half-site, while each black oval represents 
a single putative p53 half-site. (B) Chromatin immunoprecipitation assay was performed 
on A431 and HaCaT cells wherein chromatin was immunoprecipitated with normal IgG 
control antibody or antibodies that recognize all p63 isoforms or p63α isoforms as 
indicated. Eluted DNA was PCR-amplified with primers specific for multiple regions of 
the pten promoter as shown in (A). The 5’ locations of primers used are indicated in 





Because mutant p53 has previously been demonstrated to complex with p63 and 
affect the binding of p63 to its transcriptional targets, the binding of p53 to the pten 
promoter was also evaluated in these cells (Gaiddon et al., 2001; Strano et al., 2002). p53 
was found to bind nearly all of the same regions of the pten promoter as p63 (Figure 13). 
Region E, which showed binding by p63 failed to show binding by p53 in either A431 or 
HaCaT cells, while regions A and B showed strong binding of both p63 and p53. 
Interestingly, the mutant p53 in A431 cells failed to bind the p21 promoter, a known 
target of wild type p53, suggesting that this mutation severely disrupts the normal binding 
pattern of p53 and is consistent with previous reports (Park et al., 1994; Rolley et al., 
1995). Contrary to prior studies, the results shown in Figure 13 suggest that while mutant 
p53 may interact with p63 it does not prevent p63 from binding to the promoter of pten 
(Gaiddon et al., 2001; Strano et al., 2002). However, we cannot discern from these 
experiments if mutant p53 physically interacts with ΔNp63α or whether mutant p53 
influences where p63 binds the pten promoter or vice versa. These results show that 
endogenous ΔNp63α is capable of binding to the pten promoter in A431 and HaCaT cells 
in multiple locations unique to p63 in addition to binding the p53 RE.   
To confirm that p63 binding of the pten promoter correlated with a decrease in the 
transcriptional activity of pten, the effect of ΔNp63α on the transcriptional activity of a 
luciferase reporter containing the full-length pten promoter (PTEN-Luc) was analyzed. 
The p63 null cell line H1299 was co-transfected with the PTEN-Luc reporter and either 
ΔNp63α or empty vector control. Consistent with the ChIP results, ΔNp63α 
overexpression led to a statistically significant reduction (p<0.05) in PTEN-Luc reporter 
activity as well as protein levels when compared to vector transfected control cells 
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(Figure 14A). Conversely, when ΔNp63α was silenced in HaCaT cells the PTEN-Luc 
reporter activity increased, albeit to a more modest degree, as did the protein levels of 
endogenous PTEN (Figure 14B).  
In order to define which regions within the pten promoter were critical for 
ΔNp63α mediated repression of pten transcriptional activity, a series of minimal 
luciferase reporters were created based on the areas of the pten promoter to which p63 
bound. These minimal PTEN-luc reporters contained smaller fragments of the pten 
promoter than the corresponding regions pulled down in the ChIP assays (Figure 12B), 
encompassing only the putative p63 REs. When co-transfected into H1299 cells with 
ΔNp63α only the minimal PTEN-Luc reporter corresponding to Region B of the pten 
promoter showed a significant change in luciferase activity, suggesting that this region is 
critical for ΔNp63α-mediated repression of PTEN (Figure 15). Region B contains five 
p63 half sites (sequence shown in Figure 13C, lower panel), and the density of the p63 
REs within this region may explain why it is so potent at repressing PTEN expression. 
However, because the minimal PTEN-Luc reporters lack most of the PTEN promoter, we 
cannot determine if the lack of change in luciferase activity in response ΔNp63α by the 
other minimal reporters is due to the possible deletion of co-factor binding sites or simply 
that these regions are unnecessary for ΔNp63α mediated repression of PTEN. 
Nonetheless, these results demonstrate that ΔNp63α binds to the pten promoter, in a 
region distinct from other p53 family members, and negatively regulates PTEN 







Figure 13: p53 occupies many of the same locations of the pten promoter as p63. 
Chromatin immunoprecipitation assays were performed on A431 and HaCaT cells 
wherein chromatin was immunoprecipitated with normal IgG control antibody or an 
antibody specific to p53 as indicated. Eluted DNA was PCR-amplified with primers 
specific for multiple regions of the pten promoter. Specific nucleotide locations of the 
regions amplified are shown in parentheses. The p21 promoter was used as a positive 
control, however A431 cells harbor a mutation in p53 that affects DNA contact and may 








Figure 14: ΔNp63α reduces transcriptional activity of the pten promoter. (A) Dual 
luciferase assays preformed on H1299 cells co-transfected with the full-length PTEN-Luc 
reporter and empty vector or ΔNp63α. (B) Dual luciferase assays performed on HaCaT 
cells after knockdown of p63 by siRNA. Y-axis represents change in relative luciferase 
units compared to control transfected cells. Representative immunoblots are shown below 








Figure 15: Definition of the ΔNp63α-responsive elements in the pten promoter. (A) 
Dual luciferase assays in H1299 cells after co-transfection with the Full-length (FL) 
PTEN-luc reporter or the designated minimal PTEN-luc reporter and either empty vector 
or ΔNp63α expression plasmids. Minimal reporter plasmids correspond to the regions of 
the pten promoter pulled down by ChIP assay from Figure 12B. The sequence 
corresponding to region B is shown below, with the core sequence of the putative p63 
response elements bolded and underlined. Lined up underneath each p63 half site is the 
canonical p63 response element where R = purines, W = A or T and Y = pyrimidines. 




C. Activation of the Akt pathway via ΔNp63α-mediated PTEN repression.  
The most well-known function of PTEN is to dephosphorylate PIP3 and thereby 
inhibit the Akt survival pathway. To determine if the regulation of PTEN by ΔNp63α 
affects the Akt pathway, increasing concentrations of ΔNp63α were transfected into p63 
null, PTEN positive H1299 cells. Forced expression of ΔNp63α led to a dose-dependent 
reduction in endogenous PTEN protein levels with a concomitant increase in active Akt 
as measured by phospho-serine 473 levels, hereafter referred to as p-Akt (Figure 16A). 
Induction of p-Akt by ΔNp63α is dependent on ΔNp63α-mediated repression of PTEN as 
overexpression of ΔNp63α in PTEN null PC3 cells failed to increase p-Akt levels (Figure 
16B).  
Since activated Akt has been show to increase the levels of ΔNp63α and ΔNp63α 
can repress the expression of PTEN, it was next determined if ΔNp63α and constitutively 
active Akt (CA-Akt) could synergistically decrease PTEN levels (Segrelles et al., 2006). 
ΔNp63α alone led to a dramatic reduction in endogenous PTEN when overexpressed in 
H1299 cells, while CA-Akt alone led to a more modest decrease in PTEN (Figure 17). 
Consistent with previous reports, an enhancement of ΔNp63α protein was observed when 
ΔNp63α and CA-Akt were co-expressed (Barbieri et al., 2003; Segrelles et al., 2006). Co-
expression of ΔNp63α and CA-Akt, however, did not synergistically reduce PTEN 
expression as compared to overexpression of only ΔNp63α, but was capable of further 
reducing PTEN as compared to CA-Akt or vector alone conditions (Figure 17). The 
inability of ΔNp63α and CA-Akt to act synergistically in reducing PTEN levels is 
consistent with ΔNp63α and Akt functioning in the same pathway rather, but may also be 







Figure 16: Exogenous ΔNp63α induces Akt activation via down regulating PTEN. 
(A) H1299 cells were transfected with decreasing amounts of ΔNp63α expression 
plasmid as indicated. (B) PTEN null PC3 cells were transfected with empty vector or 
ΔNp63α and subjected to immunoblot analysis for the indicated proteins. The level of 









Figure 17: ΔNp63α and constitutively active Akt do not synergistically decrease 
PTEN. H1299 cells were transfected with ΔNp63α alone or together with constitutively 
active Akt (CA-Akt) and whole cell lystates were subject to immunoblot analysis as 
indicated. The change in ΔNp63α and PTEN protein levels normalized to β-actin is listed 




Forced expression of ΔNp63α in p63 null cells increased p-Akt levels by reducing 
the expression of PTEN. To determine if the same pathway was functioning in p63 
positive keratinocytes, ΔNp63α levels were knocked down with three different siRNA 
(Figure 18A). Silencing ΔNp63α led to an increase in endogenous PTEN corresponding 
with decreased p-Akt levels (Figure 18A). Knockdown of PTEN in HaCaT cells resulted 
in increased p-Akt levels, as expected, but also caused significant increases in ΔNp63α 
expression (Figure 18B). Interestingly, silencing both ΔNp63α and PTEN resulted in p-
Akt levels similar to that of control transfected cells (Figure 18A). To confirm that the 
increases in ΔNp63α observed upon loss of PTEN were indeed caused by activation of 
the Akt pathway, primary neonatal HEKs (NHEKs) were treated with the Akt specific 
inhibitor MK2206 after knockdown of PTEN. Incubation with MK2206 prevented the 
increase in ΔNp63α levels caused loss of PTEN (Figure 19). Altogether, this confirms 
that ΔNp63α and PTEN function within a regulatory loop to control p-Akt levels, which 





D. The ΔNp63α/PTEN/pAkt Regulatory loop controls keratinocyte proliferation.  
 The Akt pathway is well known for promoting cell survival and proliferation. In 
order to examine whether the control of p-Akt by the ΔNp63α-PTEN regulatory loop 
maintains cell proliferation rates, colony formation assays were performed after silencing 
ΔNp63α and/or PTEN. Silencing ΔNp63α reduced colony formation (Figure 20A-B), 
while silencing PTEN not only led to an increase in total colony number (Figure 20B), 
but also in colony size (Figure 20C) in both A431 and HaCaT cells. Simultaneous 
knockdown of ΔNp63α and PTEN did not statistically alter colony number (Figure 20B) 
or size (Figure 20C) as compared to non-silencing control transfected cells. Silencing of 
ΔNp63α and PTEN was confirmed by immunoblot analysis as shown in Figure 20B.  
Consistent with the colony formation assays, cell proliferation determined by 
MTS assays also demonstrated that silencing both ΔNp63α and PTEN resulted in 
proliferation rates similar to control transfected cells (Figure 21A). Loss of only ΔNp63α 
or PTEN resulted in decreased or increased proliferation rates, respectively. Cell 
proliferation was also measured by trypan blue exclusion in A431 and HaCaT cells after 
transfection with p63 and/or PTEN specific siRNA (Figure 21B). When measured by 
MTS assays A431 cells did not show much reduction in proliferation in response to 
silencing ΔNp63α alone as compared to the reduced rates measured by colony forming 
and trypan blue assays (Figure 21A vs Figures 20B and 21B). This may be due to the 
indirect measurement of metabolizing cells in MTS assays, rather than directly measuring 
the increase in cell number over time as with colony formation and trypan blue assay. 
Despite the discrepancies between methodologies, the results clearly show that a tight 
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balance between ΔNp63α and PTEN expression must be met in order to maintain normal 









Figure 18: ΔNp63α affects Akt activation by regulating PTEN expression.  (A) 
HaCaT cells were transfected with three different siRNAs targeting p63 or NSC as 
indicated and whole cell extracts were subjected to immunoblot analysis as indicated. (B) 
HaCaT cells were transfected with NSC or siRNA against p63 and/or PTEN and whole 
cell lystates were subject to immunoblot analysis as indicated. The change in protein 








Figure 19: PTEN influences ΔNp63α levels via inhibition of Akt activity. Primary 
neonatal human epidermal keratinocytes (NHEKs) were transfected with NSC or PTEN 
specific siRNA followed by DMSO control or 10 μM MK2206 to specifically inhibit Akt 
activity. Immunoblot analyses for the indicated proteins were performed on whole cell 
lysates; the changes in protein levels, relative to NSC DMSO treated cells, are listed 








Figure 20: A balance between ΔNp63α and PTEN controls cell proliferation. (A) 
Representative images of crystal violet stained colonies 3 days post re-seeding of 
transfected cells with NSC siRNA, p63 siRNA and/or PTEN siRNA as indicated. (B) 
Analysis of total colony number after knockdown of p63 and/or PTEN. Y-axis represents 
total number of colonies from (A) as counted with ImagePro 6.2. Error bars represent 
standard deviation. *= p<0.05. Knockdown was confirmed by immunoblot analysis and a 









Figure 21: Concomitant silencing of ΔNp63α and PTEN return growth rate to 
normal. A431 and HaCaT cells were transfected with NSC siRNA, p63 siRNA and/or 
PTEN siRNA as indicated and re-plated 24hr post transfection. The change in 
proliferation rates were measure by (A) MTS assays or (B) trypan blue staining for 
viability. (A) The Y–axis represents the change in absorbance relative to day 1. (B) The 
Y–axis represents total cell number. Error bars representing standard deviation within a 




E. ΔNp63α and PTEN expression and localization in non-melanoma skin cancers.  
The balance between ΔNp63α and PTEN was shown to be critical for regulating 
proliferation rates in cell culture (Figure 20-21), while in the clinical setting elevated 
levels of ΔNp63α have been reported in a variety of squamous and basal cell carcinomas 
(SCC and BCC, respectively) (Di Como et al., 2002; Nylander et al., 2000; Parsa et al., 
1999). To determine if the amplification of ΔNp63α seen in human non-melanoma 
cancers coincided with reduced PTEN, the expression and localization of both p63 and 
PTEN were examined by indirect immunofluorescence using a tissue microarray 
consisting of normal skin cores (n=9), hyperplastic epidermal tissue (n=7), benign basal 
cell papillomas (n=6), cores of human papilloma virus (HPV) induced condyloma 
acuminatum (n=9), BCC cores (n=11), and SCC cores (n=11). The influence of the 
ΔNp63α-PTEN axis on tumor development could also be evaluated because the tissue 
microarray contained benign overgrowths (hyperplasia, papillomas and condylomas) in 
addition to cancerous tissue (BCC and SCC). Representative images of PTEN and 
ΔNp63α expression in each of the tissue types is shown in Figure 22. 
A statistically significant increase in p63 staining (ANOVA F5,54=12.700; 
p<0.001), as measured by the mean fluorescence intensity (MFI), was observed in 
hyperplastic skin, condylomas and BCC as compared to normal epidermal tissue (Figure 
23A). p63 expression was highest in HPV induced condyloma acuminatum samples, 
most likely due to the presence of HPV and its ability of inhibit mir-203 mediated 
suppression of p63 (Melar-New and Laimins, 2010). While there was a trend towards 
increased p63 levels in benign papillomas and SCC as compared to normal tissue, it was 
not statistically significant. Except in papillomas, p63 expression was highest in benign 
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or locally invasive neoplasms, suggesting that p63 expression is important in tumor 
development but not necessarily for invasion. Increasing the sample size for each type of 
diseased tissue would clarify whether these trends are truly representative of p63 
expression in the early stages of tumor development. 
A significant correlation was observed between the MFI values of p63 and PTEN 
in normal tissue (r=0.693, p=0.042), as well as in BCC (r=0.6687, p=0.00268) and SCC 
(r=0.7356, p=0.012). While there was no decrease in PTEN staining accompanying the 
increased p63 in diseased skin, it is the overall ratio of p63 to PTEN that governs 
proliferation as demonstrated in Figures 20-21. A statistically significant difference 
(ANOVA F5,53=12.37; p<0.001) in the ratio between p63 and PTEN was observed in 
condylomas and cancerous tissues (Figure 23B), highlighting the importance of balance 
between ΔNp63α and PTEN.  
In all tissue types p63 was only observed in nuclei. In normal tissue PTEN 
staining was most abundant in the cytoplasm of epidermal keratinocytes (Figure 24, top 
left panel). A few cells with intense PTEN staining were seen in the dermis and in 
melanocytes, consistent with earlier reports (Luukko et al., 1999). Within the dermis of 
most cancerous tissue samples, intense staining for PTEN was observed in areas of solar 
elastosis, partially due to some non-specific uptake of secondary antibodies by these 
damaged fibers (Figure 24, bottom left panel). It is important to note, however, that these 
cells are of mesenchymal origin, do not express any p63 and are not the sites of origin for 
non-melanoma skin cancers. Interestingly, in both BCC and SCC very little nuclear 
PTEN was observed in the cancerous tissue, with a robust lack of nuclear PTEN observed 






Figure 22: ΔNp63α and PTEN expression in normal and diseased skin. 
Representative images from indirect immunofluorescence performed on a tissue 
microarray containing multiple cores of normal human skin, hyperplastic skin, 
precancerous lesions (benign papillomas and HPV induced condyloma acuminatum) and 








Figure 23: The balance between ΔNp63α and PTEN expression is upset in NMSC. 
(A) Quantification of the mean fluorescence intensity for p63 and PTEN staining, in 
arbitrary units, from normal epidermal tissue, hyperplastic epidermis (Hyper.), benign 
papillomas (Pap.), HPV induced condyloma acuminatum (Cond.), basal cell carcinoma 
(BCC), and squamous cell carcinomas (SCC). Error bars represent standard error of the 
mean. (B) The average ratio of p63 fluorescence intensity to PTEN fluorescence intensity 








Figure 24: Absence of nuclear PTEN in non-melanoma skin cancers. Representative 
images of PTEN staining from normal human skin, basal cell carcinoma (BCC), and 
squamous cell carcinoma (SCC) are shown. The right two columns are magnified images 
from the areas surrounded by a box in the left column to better illustrate the subcellular 
distribution of PTEN. The absence of nuclear PTEN in normal and cancerous epidermal 
tissue is shown from the lack of co-localization with DNA (DAPI, blue) or p63 (green) in 




F. ΔNp63α suppresses nuclear PTEN expression.  
To better understand how ΔNp63α affects the nuclear levels of PTEN, the 
subcellular distribution of PTEN in the epidermis of adult human (Figure 25A) and E18.5 
mouse (Figure 25B) skin was examined. In both adult and embryonic skin, keratinocytes 
of the basal layer and hair follicles expressed the highest levels of p63 with nearly 
complete nuclear exclusion of PTEN (Figure 25A-B). Moreover, PTEN staining was only 
observed in the nucleus of supra-basal layer cells that no longer expressed ΔNp63α. 
ΔNp63α expression is normally down-regulated as keratinocytes differentiate and move 
upward into the superficial layers of the epidermis. However, in keratinocytes of the 
supra-basal layer which have yet to degrade ΔNp63α no nuclear PTEN is observed 
(Figure 25A-B, marked by asterisk). This is consistent with reports demonstrating that 
nuclear PTEN is most abundant in differentiated cells, while ΔNp63α is associated with 
proliferating cells (Gimm et al., 2000).  
In order to determine if ΔNp63α suppresses nuclear PTEN, the effects of 
silencing ΔNp63α on nuclear and cytoplasmic PTEN levels were measured. Loss of 
ΔNp63α increased both nuclear and cytoplasmic levels of PTEN (Figure 26A). 
Conversely, overexpression of ΔNp63α led to a marked reduction of cytoplasmic PTEN 
with a corresponding increase in cytoplasmic p-Akt levels. A small, but reproducible, 
decrease in nuclear PTEN expression was observed after overexpression of ΔNp63α that 
correlated with a robust increase in nuclear p-Akt (Figure 26B). Furthermore, nuclear 
PTEN levels were also increased after knockdown of ΔNp63α in intact HaCaT cells as 
determined by immunofluorescence (Figure 27). Together, these studies demonstrate that 









Figure 25: PTEN is not present in the nucleus of healthy basal layer keratinocytes. 
Indirect immunofluorescence was performed on (A) normal adult human skin and (B) 
E18.5 mouse skin. Representative images for nuclei (DAPI, blue), p63 (green), and 
PTEN (red) are shown for each skin type. Basal layer cells that lack nuclear PTEN are 








Figure 26: ΔNp63α suppresses nuclear PTEN. (A) HaCaT cells were transfected with 
NSC or p63 specific siRNA and subjected to sub-cellular fractionation. Immunoblot 
analysis of the indicated proteins is shown in the left panel. Nuclear protein levels were 
normalized to the intensity of PARP, while α-tubulin served as a loading control for 
normalization of cytoplasmic proteins. The change in protein level, normalized to the 
respective loading control and relative to NSC transfected cells, is listed above each 
band. (B) H1299 cells were transfected with empty vector or ΔNp63α prior to sub-








Figure 27: Knockdown of ΔNp63α increases nuclear PTEN. HaCaT cells were 
transfected with NSC or p63 specific siRNA and subjected to indirect 
immunofluorescence for p63 (red) and PTEN (green). Nuclei are shown with DAPI 





G. ΔNp63α regulates PTEN ubiquitination via the E3 ligase NEDD4-1. 
Retention of PTEN within nucleus is maintained by a balance between nuclear 
import and export. Previous studies have implicated multiple ways by which PTEN is 
translocated into the nucleus (Chung et al., 2005; Liu et al., 2005a; Trotman et al., 2007). 
Examination of a gene expression microarray conducted on the HaCaT and A431 
keratinocyte lines after knockdown of p63 revealed the E3 ligase NEDD4-1, the first 
ligase shown to control the subcellular distribution of PTEN (Trotman et al., 2007), to be 
a potential transcriptional target of ΔNp63α (data not shown). To test the hypothesis that 
ΔNp63α regulates PTEN ubiquitination via the E3 ligase NEDD4-1, the ubiquitination of 
endogenous PTEN was first measured after transfection of p63 null cells with 
hemagglutinin tagged ubiquitin (HA-Ub) together with either empty vector or ΔNp63α 
expression plasmids. Overexpression of ΔNp63α reduced the levels of ubiquitinated 
endogenous PTEN, detected as higher migrating smears by Western blot with an anti-
PTEN antibody following immunoprecipation of HA-tagged ubiquitin (Figure 28A). The 
reduction in ubiquitinated PTEN in response to overexpression of ΔNp63α correlated 
with a decrease in NEDD4-1 expression (Figure 28A). To ensure that the reduction in 
ubiquitination of PTEN was not simply a by-product of increased transcriptional 
repression of PTEN, the effects of ΔNp63α overexpression on ubiquitination of 
exogenous PTEN was also measured. Similar to the effects on endogenous PTEN, 
ΔNp63α clearly reduced the levels of exogenous PTEN (Figure 28B). Forced expression 
of PTEN, consistent with previous reports (Ahn et al., 2008), reduced the levels of 
endogenous NEDD4-1 impeding interpretation of the effects of ΔNp63α on NEDD4-1 
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mediated ubiquitination of PTEN from this experiment (Figure 28B). Nonetheless, these 







Figure 28: ΔNp63α decreases ubiquitination of PTEN.  (A) H1299 cells were 
transfected with HA tagged ubiquitin (HA-Ub) and either empty vector or ΔNp63α 
expression plasmids. Endogenous ubiquitinated PTEN was immunoprecipitated with an 
anti-HA antibody and detected by anti-PTEN antibodies by Western blot. The change in 
protein levels, relative to vector transfected cells, in the input lysate is listed below each 
band. (B) H1299 cells were transfected with the 6xhistidine tagged ubiquitin (His-Ub) 
and the indicated expression plasmids. Ubiquitinated proteins were isolated using Ni-
NTA beads and ubiquitination of exogenous PTEN was detected as higher migrating 








Figure 29: Exogenous ΔNp63α decreases NEDD4-1 in a dose-dependent manner. 
H1299 cells were transfected with decreasing concentrations of ΔNp63α as indicated and 
whole cell extracts were subjected to immunoblot analysis for the indicated proteins. The 
change in NEDD4-1 protein levels, relative to vector transfected cells after normalization 









Figure 30: ΔNp63α represses NEDD4-1 in primary cells.  (A) Whole cell extracts 
from wild-type and p63 null MEFs were subjected to immunoblot analysis for the 
indicated proteins. The changes in proteins levels, relative to wildtype, are plotted above 
each band. Note: p63 was undetectable at the protein level. (B) Primary adult human 
epidermal keratinocytes were transfected with NSC siRNA or siRNAs targeting all 
isoforms of p63. Total RNA was extracted and transcript levels of p63 and NEDD4-1 
were analyzed by qRT-PCR. Y-axis represents the change in PTEN and p63 transcript 
levels relative to NSC transfected cells. Representative immunoblots of p63 and PTEN 
are shown in the bottom panels. The change in protein levels, relative to NSC transfected 








Figure 31: ΔNp63α represses NEDD4-1 in transformed cells.  (A) A431 and (B) 
HaCaT cells were transfected with non-silencing control (NSC) siRNA or siRNAs 
targeting all isoforms of p63. Total RNA was extracted and transcript levels of p63 and 
NEDD4-1 were analyzed by qRT-PCR. Y-axis represents the change in transcript levels 
relative to NSC transfected cells. Representative immunoblots of p63 and NEDD4-1 are 
shown in the bottom panels. The change in protein levels relative to NSC transfected 








Figure 32: Selective knockdown of ΔNp63 increases NEDD4-1 in transformed cells.  
(A) A431 and (B) HaCaT cells were transfected with non-silencing control (NSC) siRNA 
or siRNA directed against only the ΔNp63 isoforms. Total RNA was extracted and 
transcript levels of p63 and NEDD4-1 were analyzed by qRT-PCR. Y-axis represents the 
change in transcript levels relative to NSC transfected cells. Representative immunoblots 
of p63 and NEDD4-1 are shown in the bottom panels. The change in protein levels 




To better ascertain if ΔNp63α is mediating ubiquitination of PTEN by regulating 
NEDD4-1, the expression of NEDD4-1 was measured after forced expression of 
ΔNp63α. Overexpression of ΔNp63α led to a dose-dependent decrease in NEDD4-1 
expression (Figure 29). Moreover, NEDD4-1 protein levels were 7.45 times higher in 
p63-/- MEFs compared to wild type cells (Figure 30A). Because p63 null mice do not 
produce keratinocytes, the change in NEDD4-1 levels was measured after knockdown of 
p63 in primary adult human keratinocytes (Figure 30B). Knockdown of p63 with two 
different pan-p63 siRNAs lead to increased levels of NEDD4-1 transcript and protein 
levels as compared to control transfected cells (Figure 30B). The induction of NEDD4-1 
after silencing p63 was shown not be dependent on transformation status or cell line, as 
knockdown of p63 also increased NEDD4-1 transcript and protein levels in HaCaT 
(Figure 31A) and A431 (Figure 31B) cells. The use of ΔNp63 specific siRNA further 
confirmed that ΔNp63α negatively regulates NEDD4-1in both HaCaT (Figure 32A) and 
A431 cells (Figure 32B). 
 In addition to mediating the subcellular localization of PTEN, NEDD4-1 can also 
lead to poly-ubiquitin mediated proteosomal degradation of PTEN (Wang et al., 2007). 
To test whether knockdown of NEDD4-1 could synergize with silencing of ΔNp63α to 
further enhance PTEN expression, ΔNp63α and NEDD4-1 were simultaneously knocked 
down in HaCaT cells. Consistent with the ability to transcriptionally repress PTEN, 
knockdown of ΔNp63α led to increased levels of PTEN (Figure 33). Silencing of 
NEDD4-1, which can down regulate PTEN expression by poly-ubiquitin mediated 
proteosomal degradation, also led to increased levels of PTEN (Wang et al., 2007). 
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Concomitant knockdown of both ΔNp63α and NEDD4-1, however, did not further 
increase whole cell levels PTEN levels (Figure 33).   
Since loss of NEDD4-1 did not synergize with knockdown of ΔNp63α to increase 
whole cell levels of PTEN, it was speculated that the relationship between ΔNp63α and 
NEDD4-1 was controlling the subcellular distribution of PTEN within keratinocytes 
instead. To test this possibility, the ability of NEDD4-1 to restore ubiquitination of PTEN 
after forced expression of ΔNp63α was next measured. Similar to the results in Figure 
28B, forced expression of ΔNp63α dramatically reduced the levels of ubiquitinated 
PTEN (Figure 34). Co-expression of both NEDD4-1 and ΔNp63α attenuated the effects 
of ΔNp63α on ubiquitination of PTEN (Figure 34).  
Although ΔNp63α appeared to reduce both mono-ubiquitinated and poly-
ubiquitinated PTEN as evidenced by the decrease in all molecular weights of 
ubiquitinated PTEN in Figures 28 and 34, poly-ubiquitination of PTEN by NEDD4-1 has 
been shown to be predominantly comprised of lysine 63 linked ubiquitin chains (Guo et 
al., 2012). Lysine 63 linked ubiquitin chains are correlated with both signal transduction 
and proteasome mediated degradation, unlike lysine 48 ubiquitin chains which are 
predominantly degradation signals (Pickart and Fushman, 2004; Thrower et al., 2000). To 
determine if ΔNp63α mediated repression of NEDD4-1, and the subsequent reduction in 
PTEN ubiquitination, could act as a signaling event to mediate nuclear levels of PTEN in 
keratinocytes, the levels of nuclear PTEN were measured after silencing both ΔNp63α 
and NEDD4-1 in HaCaT cells. Knockdown of p63 in HaCaT cells increased NEDD4-1 
levels and also increased both nuclear and cytoplasmic PTEN (Figure 35). Conversely, 
loss of NEDD4-1 resulted in reduced nuclear PTEN levels, but increased cytoplasmic 
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levels of PTEN (Figure 35). Concomitant knockdown of ΔNp63α and NEDD4-1 
attenuated the increase in nuclear PTEN as compared to knockdown of only ΔNp63α, 
suggesting that inhibition of NEDD4-1 by ΔNp63α is responsible for the suppression of 
nuclear PTEN (Figure 35). In epidermal tissue both ΔNp63α and NEDD4-1 are highly 
expressed in the basal layer (Figure 36). The localization of ΔNp63α and NEDD4-1 to 
the basal layer also correlates with the exclusion of PTEN from the nuclei of basal layer 
keratinocytes (Figure 25), demonstrating that the ability of ΔNp63α to inhibit NEDD4-1 
mediated ubiquitiantion of PTEN inhibits the nuclear translocation of PTEN in vivo as 
well as in vitro. Altogether, these data strongly suggest that ΔNp63α is able to inhibit 
nuclear levels of PTEN by inhibiting the ubiquitination of PTEN by NEDD4-1 (Figure 








Figure 33: ΔNp63α and NEDD4-1 negatively regulate endogenous PTEN expression.  
HaCaT cells were transfected with NSC or siRNA against p63 and/or NEDD4-1 and 
whole cell lysates were subject to immunoblot analysis for the indicated proteins. The 
change in protein levels, relative to NSC transfected cells after normalization to 











Figure 34: NEDD4-1 rescues ΔNp63α-mediated reductions in PTEN ubiquitination.  
H1299 cells were transfected with 6xhistidine tagged ubiquitin (His-Ub) and the 
indicated expression plasmids. Ubiquitinated proteins were isolated using Ni-NTA beads 
and ubiquitination of exogenous PTEN and ΔNp63α were detected as higher migrating 
smears by Western blot. The change in total protein levels as detected from the input 








Figure 35: ΔNp63α and NEDD4-1 antagonistically regulate nuclear PTEN levels.  
(A) HaCaT cells were transfected with NSC or siRNA against p63 and/or NEDD4-1 and 
subjected to subcellular fractionation one day post transfection. Immunoblot analysis of 
the indicated proteins is shown in the left panel. Nuclear protein levels were normalized 
to the intensity of PARP, while α-tubulin served as a loading control for normalization of 
cytoplasmic proteins. (B) The change in protein level from three independent 
experiments is plotted. Y-axis represents the change PTEN levels relative to NSC 








Figure 36: ΔNp63α and NEDD4-1 expression is high in the basal layer of epithelial 
tissues. Representative images showing the localization of p63 (green) and NEDD4-1 
(red) in epidermal tissues from wild type E18.5 mouse embryos are shown in the top row. 
Representative images for nuclei (DAPI, blue), p63 (green), and PTEN (red) in epidermal 
tissues from wild type E18.5 mouse embryos are shown in the bottom row. Formalin 










Figure 37: Model of ΔNp63α mediated regulation of nuclear PTEN. ΔNp63α is able 
to suppress nuclear levels of PTEN by inhibiting the expression of E3 ligase NEDD4-1. 
The repression of NEDD4-1 by ΔNp63α subsequently decreases the mono-ubiquitination 
of PTEN, thereby preventing nuclear import of PTEN.   
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H. ΔNp63α influences the localization of PTEN to novel subcellular compartments. 
PTEN has many functions dependent on its location within cells. Cytoplasmic 
PTEN is most notably associated with Akt inhibition, but is also important in suppressing 
invasion and migration as well as contributing to proper cell polarization through 
dephosphorylation of PIP3 (Davidson et al., 2010; Langlois et al., 2010). Nuclear PTEN 
is important for inducing cell cycle arrest and maintaining chromosome stability; these 
processes may, at least in part, be independent of Akt inhibition (Liu et al., 2005b; Shen 
et al., 2007). Interestingly, PTEN -/- mouse embryonic fibroblasts (MEFs) escape taxol-
mediated mitotic arrest more quickly than wild type cells, suggesting that PTEN is 
important for a mitotic spindle checkpoint (Gupta et al., 2009). PTEN has also been 
implicated in the induction of genes associated with microtubule formation and/or 
stabilization (Gupta et al., 2009; Tibarewal et al., 2012). To this end, the potential of a 
mitosis-specific role for PTEN was investigated. 
Examination of mitotic cells after knockdown of p63 in HaCaT cells 
demonstrated an increase in PTEN fluorescence at discrete foci that were reminiscent of 
centrosomes (Figure 38A, quantitated in 38B). These PTEN “foci” were confirmed to be 
mitotic centrosomes by co-localization the centrosome marker γ-tubulin (Figure 39). 
Moreover, PTEN was only observed to localize at centrosomes during mitosis; there was 
little to no co-localization of PTEN with γ-tubulin during G1 or G2 in either HaCaT cells 
(Figure 39) or H1299 cells (Figure 40). Immunofluorescence labeling of PTEN at the 
centrosomes is specific, as no signal was detected in PTEN-null PC3 cells (Figure 41, top 
row). Co-localization of PTEN and γ-tubulin was detected in multiple cell lines, further 







Figure 38: Loss of ΔNp63α increases centrosomal PTEN.  (A) HaCaT cells were 
transfected with non-silencing control (NSC) or p63 specific siRNA then stained for 
PTEN (green), p63α (red) and DNA (blue) 48 hr later. Arrowheads point to the 
centrosome enlarged within the inset box. Bars = 5 μm. (B) The mean fluorescent 
intensities of p63 and centrosomal PTEN from (A) are plotted. Error bars represent s.e.m. 







Figure 39: PTEN localizes to centrosomes during all stages of mitosis in HaCaT 
cells. Actively growing asynchronous HaCaT cells were fixed and stained for PTEN 
(green), γ-tubulin (red) and DNA (DAPI, blue). Representative cells from each stage of 
the cell cycle are shown in each row. Arrowheads point to the centrosome enlarged 







Figure 40: PTEN localizes to centrosomes during all stages of mitosis in H1299 cells. 
Actively growing asynchronous H1299 cells were fixed and stained for PTEN (green), γ-
tubulin (red) and DNA (DAPI, blue). Representative cells from each stage of the cell 
cycle are shown in each row. Arrowheads point to the centrosome enlarged within the 







Figure 41: Centrosomal PTEN is not cell line specific. PTEN null PC3 cells and PTEN 
postive HaCaT, A431 and H1299 cells were stained for PTEN (green) and γ-tubulin 
(red). The PTEN +/+ cell lines show varying amounts of co-localization (observed as 
yellow in the last column) with γ-tubulin. Arrowheads indicate the centrosome enlarged 





 (Figure 41). The localization of PTEN to mitotic centrosomes was also detected with a 
second PTEN-specific antibody (Figure 42), excluding the possibility that staining of 
PTEN at mitotic centrosomes was an artifact. 
Centrosomes are critical to proper spindle assembly and chromosome separation 
during mitosis. To determine if PTEN was involved in this process, the expression of 
PTEN at mitotic centrosomes in primary keratinocytes was first examined. Primary 
neonatal human epidermal keratinocytes (NHEKs) where chosen for investigation into 
the function of centrosomal PTEN as transformed cancer cell lines can be prone to 
genomic instability and would thus confound the interpretation of how PTEN influences 
centrosome and/or chromosome integrity. Similar to HaCaT and H1299 cells, little to no 
centrosomal labeling of PTEN was observed during interphase in NHEKs (Figure 43). 
Clear localization of PTEN to centrosomes during mitosis was observed by co-staining 
with centrosome markers γ-tubulin, pericentrin (PCNT) and polo-like kinase 1 (PLK-1) 
(Figure 43). PTEN is located in the pericentrisomal matrix (PCM), as shown by co-
localization with PLK-1, PCNT, and γ-tubulin (Figure 43). Ninein, a protein associated 
with centrosomes predominantly during interphase (Chen et al., 2003), showed no co-
localization with PTEN during interphase and minimal co-localization in the few mitotic 
cells with detectable centrosomal ninein (Figure 43, last column). The intensity of PTEN 
at the centrosomes was most evident during prophase and metaphase (Figure 44), which 
coincides with the time frame for centrosome maturation (Palazzo et al., 2000). The 
relative intensity of PTEN at the PCM during mitosis was more similar to PLK-1, another 
transiently associated PCM protein, confirming the mitosis specific centrosomal 







Figure 42: Centrosome PTEN is not a staining artifact. H1299 cells were stained for 
PTEN with either Cascade Bioscience PTEN 6H2.1 (cb PTEN) or Cell Signaling rabbit 
monoclonal anti-PTEN (#9559, cs PTEN). Both PTEN images were taken at the same 
exposure time (500 ms). Nuclei were counter stained with DAPI. Arrows point to 







Figure 43: PTEN co-localizes with numerous pericentrosomal matrix proteins 
during mitosis. Actively growing, asynchronous, neonatal primary epidermal 
keratinocytes (NHEK) were fixed and stained for the indicated proteins. Representative 
cells from each stage of the cell cycle as determined by chromatin condensation and 
centrosome number are shown in each row. Arrowheads point to the centrosome enlarged 









Figure 44: Quantitation of centrosomal PTEN during mitosis. Mean fluorescence 
intensity (arbitrary units) of PTEN, PLK-1, γ-Tubulin and pericentrin (PCNT) during 
each stage of mitosis from NHEK. Error bars represent s.e.m from three independent 




I. PTEN regulates centrosome composition in both an Akt-dependent and 
independent manner. 
To determine the role of PTEN at mitotic centrosomes, the effects of PTEN 
knockdown on PCM associated proteins were examined. Immnoblot analyses of whole 
cell extracts after knockdown of PTEN in NHEKs revealed modest, but statistically 
significant increases in both PLK-1 and γ-tubulin (Figure 45). Pericentrin could not be 
consistently detected by immunoblot analysis, in part due to its large size (~330 kDa) 
affecting protein transfer, and was thus only measured during mitosis by 
immunofluorescence. Contrary to the effects on whole cell levels, knockdown of PTEN 
did not alter PLK-1 or γ-tubulin levels at centrosomes (Figure 46A, quantitated in 46B), 
but lead to a 29% reduction in centrosomal PCNT levels (Figure 46B). The difference 
between immunoblot and immunofluorescence results may be due to the fact that the 
immunofluorescence measurements were taken of only mitotic centrosomes without 
considering changes in whole cell immunofluorescence, while the Western blot analyses 
in Figures 45A measure total protein levels (at all subcellular compartments) and at all 
stages of the cell cycle. Furthermore, global changes may not always mirror the changes 
occurring at a specific cellular compartment. This is often important for driving processes 
forward while also limiting the biochemical changes of the process to a particular 
subcellular location. 
Induction of PLK-1 upon PTEN loss may occur via a phosphatase independent 
mechanism as has been reported previously in prostate cancer cells (Song et al., 2011). 
To determine if PLK-1 and γ-tubulin were similarly regulated in normal keratinocytes by 
an Akt-independent mechanism, PTEN was silenced followed by treatment with the Akt 
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inhibitor MK2206. Although MK2206 alone had little effect on whole cell levels of either 
PLK-1 or γ-tubulin (Figure 47A), inhibition of Akt activity by MK2206 completely 
blocked the increases in both PLK-1 and γ-tubulin caused by silencing PTEN (quantitated 
in Figure 47B).  
Intriguingly, inhibition of Akt with MK2206 reduced levels of PTEN, PLK-1 and 
γ-tubulin at mitotic centrosomes (representative images in Figure 48, quantitated in 
Figure 49). MK2206 had little effect on levels of PCNT at mitotic centrosomes (Figure 
50). Furthermore, inhibition of Akt with MK2206 could not rescue centrosomal levels of 
PCNT after knockdown of PTEN, indicating that PTEN is regulates PCNT through an 
Akt-independent manner (Figure 49). Altogether, these studies indicate that both PTEN 
and Akt are critical for proper association of PCNT, PLK-1 and γ-tubulin with mitotic 
centrosomes. Furthermore, the respective roles of PTEN and Akt on regulating 








Figure 45: PTEN loss increases whole cell levels of γ-tubulin and PLK-1. PTEN was 
silenced in NHEKs followed by immunoblot analysis for the indicated proteins. 
Quantification of the change in proteins levels is graphed in the right panel. Error bars 








Figure 46: PTEN differentially affects centrosome proteins. (A) PTEN was silenced 
in NHEKs then stained for the indicate proteins by immunofluorescence. (B) The mean 
fluorescent intensities of each protein at mitotic centrosomes, relative to control 
transfected cells, are plotted. Error bars represent standard error of the mean from three 
separate experiments, at least 25 centrosomes measured for each protein per condition per 
experiment. *=p values ≤ 0.05; # = p values ≤ 0.009. Arrowheads point to the centrosome 









Figure 47: PTEN influences whole cell levels of γ-tubulin and PLK-1 in an Akt 
dependent manner. (A) NHEKs were transfected with non-silencing control (NSC) or 
PTEN specific siRNA followed by 10 μM MK2206 or DMSO control. Immunoblot 
analysis for the indicated proteins was performed. (B) The change in total protein levels 









Figure 48: Akt activity regulates centrosome composition. (A) Immunofluorescence 
analysis for the indicated proteins was performed on NHEKs transfected with non-
silencing control (NSC) or PTEN specific siRNA followed by 10 μM MK2206 or DMSO 








Figure 49: Quantitation of centrosome proteins after inhibition of Akt activity. 
Immunofluorescence analysis for the indicated proteins was performed on NHEKs 
transfected with non-silencing control (NSC) or PTEN specific siRNA followed by 10 
μM MK2206 or DMSO treatment. The mean fluorescent intensities of each protein at 
mitotic centrosomes, relative to NSC/DMSO treated cells, are plotted on the right. Error 
bars represent standard error of the mean from three separate experiments, at least 25 
centrosomes measured for each protein per condition per experiment. *=p values ≤ 0.05; 




J. Both PTEN expression and Akt activity are required to prevent centrosome 
defects. 
In addition to reducing the recruitment of PCM proteins to mitotic centrosomes, 
inhibition of Akt signaling with MK2206 drastically increased the frequency of 
centrosome defects during metaphase (Figure 50). Concomitant knockdown of PTEN and 
MK2206 treatment reduced the frequency of metaphase cells with centrosome defects as 
compared to MK2206 treatment alone, but was still significantly higher than in cells 
treated with non-silencing control and DMSO (Figure 50). MK2206 treatment and PTEN 
knockdown did not drastically alter the frequency of prophase cells with centrosome 
defects compared to control treated cells (Figure 50). This may be the result of combined 
PTEN knockdown and MK2206 treatment allowing cells to progress through prophase 
without resolving defects, as it has been reported earlier that PTEN null have a deficient 
mitotic checkpoint (Gupta et al., 2009). No clear effects on centrosome number or 
structure were observed in anaphase cells (data not shown). The most common defects 
observed were fragmented centrosomes and centrosome amplification, as determined by 
staining for constitutive centrosome components PCNT and γ-tubulin (Figure 51). The 
combination of PTEN knockdown and MK2206 treatment increased the frequency of 
fragmented centrosomes (Figure 51A). Consistent with previous reports, loss of PTEN 
increased the frequency of centrosome amplification (Li et al., 2009; Nam et al., 2010). 
Inhibition of Akt with MK2206 after knockdown of PTEN reduced the number of cells 
with supernumerary centrosomes, confirming that centrosome amplification is caused by 
increased Akt activity rather than PTEN loss (Figure 51B).  
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It is important to note that even though loss of PTEN and MK2206 treatment 
increased the number of centrosome defects, no overt chromosomal abnormalities were 
observed in NHEK cells during our short term study. Because these studies were 
conducted in primary cells it indicates that disruption of the PTEN/Akt pathway is 
sufficient to cause centrosome defects but that additional mutations may be required 
before the effects on chromosome stability are detectable. Consistent with this idea, 
knockdown of PTEN alone increased the prevalence of centrosomal and chromosomal 
defects in H1299 cells, a non-small cell lung carcinoma cell line (Figure 52). The most 
common of these defects were centrosome amplification, broken chromosomes, failure of 
chromosomes to align at the metaphase plate, and anaphase bridges (examples depicted 
in Figure 52B). These defects likely contribute to the chromosome instability and 
aneuploidy that has been previously associated with PTEN loss (Gupta et al., 2009; 
Levine et al., 1998; Puc et al., 2005). Furthermore, the induction of mitotic defects in the 
absence of PTEN highlights the need for continued PTEN expression even after 








Figure 50: Concomitant loss of Akt and PTEN reduces the frequency of centrosomal 
defects observed when only Akt in inhibited. Immunofluorescence analysis for the 
indicated proteins was performed on NHEKs after treatment NSC or PTEN specific 
siRNA followed by 10 μM MK2206 or DMSO control. The number of centrosomal 
defects in each stage of mitosis was scored. Error bars represent standard deviation from 
at least five separate experiments: *=p values ≤ 0.05. No defects were observed NSC, 








Figure 51: Akt activity and PTEN are necessary to prevent centrosome defects. 
Representative images of (A) fragmented and (B) supernumerary centrosome defects. 
Arrowheads point to the centrosome enlarged within the inset box while full arrows point 
to the remaining centrosome. Bars = 5 μm. The frequency of each type of defect is 
graphed in the lower panels. Error bars represent standard deviation from at least five 








Figure 52: Silencing only PTEN is sufficient to induce mitotic defects in H1299 cells. 
(A) Asynchronously growing H1299 cells were stained for PTEN, γ-tubulin and DNA. 
The number of chromosomal and centrosomal defects scored per 100 mitotic cells per 
experiment is graphed. Error bars represent s.e.m from three separate experiments. *=p 
values ≤0.05. (B) Representative images from cells scored in (A) showing supernumerary 
centrosomes and broken chromosomes; arrows point to centrosomes or misaligned 
chromosomes, respectively. Arrowheads point to the centrosome enlarged within the 








A. Significance of transcriptional regulation of PTEN by ΔNp63α. 
At an estimated 3.5 million new cases each year, non-melanoma skin cancers 
(NMSCs) are the most common type of cancer in the United States, comprising more 
new cases each year than all other cancers combined (Rogers et al., 2010). The increase 
in NMSC frequency has reached epidemic proportions with some states showing a nearly 
350% increase in the occurrence of SCC from 1979 to 1999 (Karagas et al., 1999). By 
understanding the molecular and cellular etiology of NMSC, better treatment and 
prevention modalities can be designed. Elucidating the critical genetic paradigms 
associated with keratinocyte proliferation, and the de-regulation of these processes, is 
essential to understanding of NMSC development. Normal epidermal development is 
dependent upon the expression of the transcription factor p63 (Mills et al., 1999; Yang et 
al., 1998; Yang et al., 1999). In particular, the ΔNp63α isoform helps maintain the 
proliferative potential of keratinocytes. Amplification of ΔNp63α is also frequently 
observed in SCC, making it an excellent candidate for understanding the etiology of 
NMSC (Bircan et al., 2006; Di Como et al., 2002; Sakiz et al., 2009). 
Due to the difficulty in dissecting the molecular events involved in epidermal 
proliferation in whole tissues, many studies often employ keratinocytes culture systems. 
ΔNp63α was shown to be the predominant p63 isoform in cultured primary keratinocytes, 
the spontaneously transformed HaCaT cell line and the atypical squamous cell carcinoma 
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A431 cell line (Figure 6). In all three cell lines, knockdown of ΔNp63α led to increased 
transcript and proteins levels of PTEN (Figures 7-8), indicating that PTEN is negatively 
regulated by p63 in keratinocytes. 
ΔNp63α can function in a dominant negative manner towards p53 and the pro-
apoptotic TAp63 and TAp73 isoforms, further demonstrating the pro-proliferative nature 
of ΔNp63α and implicating it as a possible oncogene (Yang et al., 1998). The 
exponentially higher transcript levels of ΔNp63 compared to TAp63 in normal and 
cancerous keratinocytes (Figure 6), as well as the inability to detect any protein levels of 
TAp63 make it unlikely that the TAp63 isoforms exert much control over PTEN in 
keratinocytes. Furthermore, siRNAs targeting all p63 isoforms (Figure 7) resulted in 
similar inductions of PTEN to those observed with ΔNp63 specific siRNA (Figure 8), 
indicating that TAp63 is not a positive regulator of PTEN in adult keratinocytes. This is 
consistent with previous studies demonstrating that overexpression of TAp63α in 
keratinocytes led to activation of Akt, a common functional readout of decreased PTEN 
levels (Ogawa et al., 2007). Together, this suggests that p63 inhibits PTEN independently 
of any repressive effects of the ΔNp63 isoforms toward the TAp63 isoforms. 
Head and neck squamous cell carcinomas are reliant on high levels of ΔNp63α for 
survival through repression of p73-mediated apoptosis (Rocco et al., 2006). PTEN has 
previously been shown to be a direct transcriptional target of both p53 and TAp73 
(Stambolic et al., 2001; Vella et al., 2009), making it possible that ΔNp63α inhibited 
PTEN expression by impairing the ability of p53 and/or p73 to induce PTEN. In the 
HaCaT and A431 keratinocytes lines, however, the anti-apoptotic ΔNp73 isoforms are 
the predominant p73 species (Figure 10). Isoform specific knockdown of TAp73 did not 
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significantly alter PTEN levels (Figure 11B), suggesting that regulation of PTEN by the 
different p53 family members may be tissue specific. Furthermore, p63 did not bind to 
Region D of the pten promoter (Figure 12B), which corresponds to the region of the pten 
promoter previously shown to be bound by p73 in thyroid cells, suggesting that p63 and 
p73 do not compete for same responsive elements (Vella et al., 2009). The studies in 
Figures 10 to 12 suggest that, in at least HaCaT and A431 cells, TAp73 plays little role in 
the transcriptional regulation of PTEN in the absence of genotoxic stress. More studies, 
however, would need to be conducted to determine if the transcriptional repression of 
PTEN by ΔNp63α contributes to the ΔNp63α-mediated resistance of SCC cells to 
genotoxic agents like cisplatin (Rocco et al., 2006; Sen et al., 2011). 
Arguing against the possibility that ΔNp63α induced PTEN by acting in a 
dominant negative manner toward p53 was the observation of similar increases in PTEN 
after silencing ΔNp63α in A431, HaCaT and primary human epidermal keratinocytes 
(HEKs), since these cell lines all harbor different forms of p53 (Figure 7). HEKs have 
wild type p53, while A431 and HaCaT cells harbor mutant p53, R273H and 
H179Y/R282W, respectively. Interestingly, it has been shown that mutant p53 can co-
immunoprecipitate with ΔNp63α from HaCaT cells (Gaiddon et al., 2001; Strano et al., 
2002). The interaction between mutant p53 and ΔNp63α may explain why many of the 
same regions of the pten promoter to which p63 bound were also occupied by p53 
(Figure 13). However, luciferase assays showed repression of PTEN-Luc activity upon 
overexpression of ΔNp63α in the absence of any p53, mutant or wild type, demonstrating 
that p53 is not required for ΔNp63α mediated repression of PTEN transcription (Figure 
14A). Knockdown of ΔNp63α in p53 mutant HaCaT cells also alleviated the repression 
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on the activity of the PTEN-Luc construct, suggesting that even if mutant p53 bound to 
ΔNp63α it does not impede the ability of ΔNp63α to transcriptionally repress PTEN 
(Figure 14B). This may be due to fact that keratinocytes express very high levels of 
ΔNp63α and studies have shown that mutant p53 only bound ~10% of the total p63 
expressed, leaving a significant portion of p63 to control transcription of its target genes 
unimpeded (Gaiddon et al., 2001). Altogether, these studies suggest that ΔNp63α acts as 
a master regulator, independent of p53 status, to repress PTEN in keratinocytes. To truly 
confirm the ability of ΔNp63α to transcriptionally repress PTEN independently of p53, 
one would need to examine the occupancy of ΔNp63α at the pten promoter by ChIP 
analysis after knockdown of p53 in cell lines with wildtype and mutant p53 in addition to 
measuring the effect of concomitant loss of p53 and ΔNp63α on transcription rates of 
PTEN. 
Interestingly, some studies have shown a paradoxical tumor-promoting function 
for PTEN in cells expressing gain-of-function p53 mutations (Li et al., 2008). PTEN 
stabilizes p53 in phosphatase-independent and phosphatase-dependent manners; 
protecting p53 from Mdm2-mediated ubiquitination through inhibition of Akt signaling 
and through direct physical interaction (Freeman et al., 2003; Mayo et al., 2002). By 
binding to mutant p53, PTEN protects mutant p53 from Mdm2-mediated destruction 
thereby enhancing tumor growth in xenograft studies (Li et al., 2008). Since mutation of 
p53 is frequently observed in NMSC (Benjamin et al., 2008), it would be interesting to 
examine if the protection of mutant p53 by PTEN could synergize with ΔNp63α-
mediated transcriptional repression of PTEN to enhance the development of NMSC.  
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While mutations in p53 are found in 50% of all human cancers, p63 is rarely 
mutated in cancers (Hagiwara et al., 1999). Rather, ΔNp63α is overexpressed in multiple 
types of SCC and BCC, typically through amplification of the p63 locus (Bircan et al., 
2006; Choi et al., 2002; Di Como et al., 2002; Hibi et al., 2000; Hu et al., 2002; Park et 
al., 2000; Parsa et al., 1999; Sakiz et al., 2009). Overexpression of ΔNp63α in H1299 
cells, mimicking the amplification of ΔNp63α observed in NMSC, led to phosphorylation 
and activation of Akt by repressing PTEN (Figure 16). The repression of PTEN by 
ΔNp63α was found to be critical for ΔNp63α-mediated induction of Akt phosphorylation 
since overexpression of ΔNp63α was unable to induce Akt phosphorylation in PTEN null 
cells (Figure 16B). This is in contrast to a recent study by Sen et al. suggesting that Akt1 
is a direct transcriptional target of ΔNp63α (Sen et al., 2011). However, no changes in 
total Akt levels were observed upon overexpression of ΔNp63α (Figure 16) or 
knockdown of p63 (Figures 18), arguing against a direct transcriptional effect of ΔNp63α 
on Akt. Any changes that may have occurred in Akt1 in response to modulation of 
ΔNp63α levels in Figures 16-18 may have been eclipsed by using a pan-Akt antibody 
(capable of detecting Akt1, Akt2 and Akt3) rather than the Akt1 specific antibody used 
by Sen et al. (Sen et al., 2011). The dissimilarity between these two studies could further 
be due to the difference in cell lines used; the studies shown in this dissertation primarily 
utilized cell lines from a cutaneous origin while Sen et al. used ovarian cancer and head 
and neck SCC cell lines (Sen et al., 2011). While the studies presented in this dissertation 
support the indirect activation of Akt by ΔNp63α through transcriptional repression of 
PTEN, they do not entirely exclude the possibility that ΔNp63α may also induce Akt 
through direct transcriptional means. 
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In addition to ΔNp63α mediated activation of Akt, Akt can also increase ΔNp63α, 
potentially accentuating ΔNp63α-mediated repression of PTEN (Barbieri et al., 2003; 
Segrelles et al., 2006). However, while artificial proliferative signals in the form of 
ΔNp63α and CA-Akt over expression did not lead to a synergistic or additive decrease in 
PTEN expression, it did result in a larger decrease in PTEN expression compared to CA-
Akt alone (Figure 17). Activation of Akt can initiate the ARF/Egr-1 axis that leads to 
induction of PTEN (Yu et al., 2009), potentially explaining why CA-Akt was not as 
potent at repressing PTEN as ΔNp63α. The potent ability of ΔNp63α to reduce PTEN 
expression suggests that ΔNp63α amplification, even in the absence of constitutive 
activation of the PI3K/Akt pathway maybe be enough to tip the balance toward 
hyperplasia and cancer development. This is supported by studies demonstrating that 
cutaneous SCC is dissimilar from other forms of SCC in that cutaneous SCC rarely 
exhibits constitutively activating mutations in PI3K or Akt (Hafner et al., 2010).  
By inhibiting the activation of Akt, PTEN can also antagonize ΔNp63α levels as 
shown in Figure 19. Altogether, this creates a feedback loop between ΔNp63α/PTEN/Akt 
that must be finely balanced to prevent an overabundance of proliferative signals as 
diagramed in Figure 53. Loss of PTEN significantly increases the normal proliferation 
rates of keratinocyte cell lines which can be restored by concomitant knockdown of 
ΔNp63α (Figure 20-21). This is consistent with previous reports demonstrating that 
minute reductions in PTEN expression are sufficient to drive tumorigenesis and further 
highlight the delicate balance between ΔNp63α/PTEN/Akt in controlling cell 
proliferation (Alimonti et al., 2010; Trotman et al., 2003). Because of the myriad of genes 
and pathways regulated by ΔNp63α and Akt, the simplified model depicted in Figure 53 
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represents only a fraction of events required for keratinocyte proliferation. More studies 
will need to be conducted in order to determine what other pathways may contribute to 
how PTEN balances the activation of Akt and the subsequent stabilization of ΔNp63α. A 
potential pathway for future studies on keratinocytes proliferation would be the induction 
of PTEN by the Egr-1/Arf axis, considering that this axis can be triggered by Akt (Yu et 
al., 2009).  
Interestingly, the atypical squamous cell line A431 displayed the same changes in 
growth rates in response to silencing ΔNp63α and/or PTEN as HaCaT cells, suggesting 
that the ΔNp63α/PTEN axis is conserved in both atypical squamous cell carcinomas and 
non-tumorigenic cells (Figure 20). A431 cells, however, were less susceptible to changes 
in growth rates after silencing ΔNp63α and/or PTEN, when measured by MTS assay 
(Figure 21A). This may be due to the high degree of epidermal growth factor receptor 
amplification in the cells which could impact the metabolism. The indirect measurement 
of metabolizing cells in MTS assays, rather than directly measuring the increase in cell 
number over time as with colony formation and trypan blue assay, could then explain the 
inconsistencies between HaCaT and A431 cells in Figure 21A. Despite the discrepancies 
between methodologies, the results clearly show that a tight balance between ΔNp63α 
and PTEN expression must be met in order to maintain normal proliferation rates in 
keratinocytes.  
The importance of the balance between ΔNp63α and PTEN is further highlighted 
in squamous and basal cell carcinomas, the two most common cancers, where the ratio of 
p63 to PTEN is significantly perturbed (Figure 23). The amplification of ΔNp63α and the 
subsequent imbalance between ΔNp63α and PTEN in both basal cell carcinoma and 
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squamous cell carcinoma suggests that regulation of PTEN in keratinocytes relies 
primarily on ΔNp63α to control proliferation. A similar statistically significant increase 
in the ratio of p63 to PTEN was observed in samples of HPV induced condyloma 
acuminata (Figure 23B). There is strong evidence showing that HPV is involved in the 
development of some forms of skin cancer, in addition to its known role in cervical 
cancer (Faridi et al., 2011; Harwood et al., 2004; Nindl et al., 2007). Together, this study 
demonstrates that ΔNp63α maintains normal cell proliferation by negatively regulating 
basal PTEN levels to cause Akt activation and that disruption of this balance is an early 
insult that contributes to of non-melanoma skin cancer. 
The studies presented in this dissertation suggest that the repression of PTEN by 
ΔNp63α may be involved in the development of NMSC, however, tumor formation 
studies in animal models and would need to be conducted to confirm this possibility. For 
instance, one could generate a mouse model wherein ΔNp63α was over expressed in the 
epidermis while PTEN levels were reduce and measure the development of NMSC by 
two-step chemical carcinogenesis or chronic UVB irradiation. This could be 
accomplished by crossing the K5-tTA/pTRE-ΔNp63α (K5-ΔNp63α) mouse model 
developed by Satrijit Sinha (Romano et al., 2010), wherein ΔNp63α is overexpressed in 
the skin via a keratin 5 promoter, with the skin-specific PTEN knockout mouse (k5-
PTEN
+/flox
) created in the laboratory of Tak Mak (Suzuki et al., 2003). If the model 
proposed in Figure 53 is correct, the overexpression of ΔNp63α would allow mice 
heterozygous for PTEN to initially develop more tumors than PTEN
+/+
 mice, but 
overtime the enhanced repression of PTEN by ΔNp63α would cause K5-ΔNp63α; 
PTEN
+/+




 mice. Furthermore, in the absence of 
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doxycycline K5-tTA/pTRE-ΔNp63α bi-transgenic animals express ΔNp63α, allowing for 
temporal control the ΔNp63α transgene to better address the role of ΔNp63α-mediated 








Figure 53: The ΔNp63α, PTEN and Akt feedback loop controls keratinocyte 
proliferation. ΔNp63α transcriptionally represses PTEN, leading to increased Akt 
phosphorylation and activation. Active Akt also increases the levels of ΔNp63α; both 
proteins enhance cell survival and proliferation. PTEN inhibits activation of Akt, and 




B. Significance of ΔNp63α-mediated regulation of PTEN subcellular distribution. 
In addition to regulation at the transcriptional level, PTEN is also subject to post-
translational modifications and changes in subcellular distribution. In the nucleus PTEN 
has many functions that may be independent of those associated with its cytoplasmic 
localization such as cell cycle arrest (Chung and Eng, 2005; Ginn-Pease and Eng, 2003), 
protection of p53 and p73 from degradation (Lehman et al., 2011; Mayo et al., 2002) and 
maintaining chromosome stability (Gupta et al., 2009; Shen et al., 2007). Since nuclear 
PTEN is most frequently observed in G1 arrested or quiescent cells, ΔNp63α may be able 
to stimulate keratinocyte proliferation through transcriptional repression of PTEN 
(discussed above) as well as by inhibiting the nuclear translocation of PTEN (Figure 26) 
(Chung and Eng, 2005; Ginn-Pease and Eng, 2003; Jacob et al., 2009; Whiteman et al., 
2002). The ability of ΔNp63α to support keratinocyte proliferation by controlling PTEN 
localization is supported by the absence of PTEN from the nuclei of basal layer 
keratinocytes, which are the proliferative cells of the epidermis, while PTEN is abundant 
in the nuclei of non-proliferating, differentiated cells of the upper epidermis (Figure 25). 
The dramatic lack of nuclear PTEN in both BCC and SCC (Figure 27), presumably due 
in part from amplification of ΔNp63α, might prevent cells from undergoing a proper cell 
cycle arrest or differentiation program and thus allow for cancer development. In 
melanoma the loss of nuclear PTEN is associated with cancer progression and could be 
used as a prognostic marker (Whiteman et al., 2002). Given that little nuclear PTEN is 
observed in basal layer keratinocytes of normal skin (Figure 25), it is unlikely that the 
lack of nuclear PTEN seen in BCC and SCC could be used as a prognostic marker as 
with melanoma (Figure 24).  
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In order to determine if the repression of nuclear PTEN by ΔNp63α was 
contributing to enhanced proliferation more experiments would need to be conducted. For 
example, if the lack of nuclear was allowing keratinocytes to proliferate one would 
expect to observe decreased proliferation, potentially measured by MTS assays or colony 
forming ability, after transfection of PTEN harboring a nuclear localization signal to 
force expression of PTEN in the nucleus. Furthermore, expression of a PTEN construct 
that was locked in the cytoplasm, either through introduction of a nuclear exclusion 
signal or mutation of lysine 289 to prevent import of PTEN into the nucleus, should 
rescue the effects on keratinocyte proliferation after silencing ΔNp63α. 
Modulation of ΔNp63α expression was able to affect nuclear PTEN in both 
HaCaT and H1299 cells, albeit to varying degrees, suggesting that the ability of ΔNp63α 
to repress nuclear PTEN is not restricted to keratinocytes (Figure 26). Knockdown of 
ΔNp63α in HaCaT cells was clearly able to increase nuclear levels of PTEN (Figure 
26A). H1299 cells already had a low nuclear to cytoplasmic ratio of PTEN, and thus the 
reduction in nuclear PTEN caused by over expression of ΔNp63α was less pronounced 
than the changes observed in HaCaT cells (Figure 26B). Despite the discrepancies in the 
magnitude of change between the cell lines, high levels of ΔNp63α in either cell line 
correlated with low levels of nuclear PTEN and subsequent increases in nuclear phospho-
Akt levels. The inverse relationship between nuclear PTEN and nuclear phosphorylated 
Akt supports the recent study by Dr. Charis Eng’s laboratory showing that nuclear PTEN 
is necessary and sufficient for inhibiting nuclear Akt (He et al., 2012). More studies, 
however, should also be conducted to determine if the Akt-independent functions of 
PTEN, such the binding of CENP-C or the APC/Cdh1 mediated degradation of PLK-1 
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(Shen et al., 2007; Song et al., 2011), are also affected by modulation of ΔNp63α. This 
could be accomplished by studying the effects of concomitant overexpression of ΔNp63α 
and a phosphatase–dead PTEN mutant, such as C124S PTEN, on chromosome stability 
and cell cycle arrest. 
ΔNp63α was found to inhibit nuclear levels of PTEN by inhibiting the 
ubiquitination of PTEN by NEDD4-1 as diagramed in Figure 37. By negatively 
regulating the expression of NEDD4-1 (Figures 29-32), p63 was able to indirectly control 
the ubiquitination (Figure 27 and 34), and thus the localization, of PTEN (Figures 35). 
While exogenous NEDD4-1 did not increase ubiquitination of PTEN over baseline levels 
in H1299 cells, it sufficiently blocked ΔNp63α-mediated reductions in PTEN 
ubiquitination (Figure 34). The increases in whole cell levels of PTEN (Figure 33) and 
the reduction in nuclear PTEN (Figure 36) caused by knockdown of NEDD4-1 in HaCaT 
cells would suggest that NEDD4-1 is in fact ubiquitinating PTEN. The inability to detect 
the ubiquitination of PTEN by exogenous NEDD4-1 could be the result of the 
overexpression system used, perphaps though insufficient supply of NEDD4-1 co-factors, 
and further ubiquitination studies should be conducted in keratinocytes after knockdown 
of endogenous NEDD4-1 to confirm this possibility. ΔNp63α could also regulate the 
ubiquitination of PTEN by competing for binding to NEDD4-1. This is supported by 
previous studies showing that ΔNp63α is also ubiquitinated by NEDD4-1 leading to its 
destabilization (Bakkers et al., 2005). 
Despite the strong circumstantial evidence pointing to the regulation of PTEN 
ubiquitination by ΔNp63α to be via inhibition of NEDD4-1, ΔNp63α may also inhibit the 
ubiquitination of PTEN through additional mechanisms. Microarray analyses conducted 
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previously in the laboratory identified several genes potentially regulated by ΔNp63α that 
could theoretically alter the ubiquitination of PTEN. The microarray studies, performed 
after knockdown of p63, demonstrated that p63 may positively regulate the expression of 
ubiquitin specific protease 31 (USP31). USP31 catalyzes the removal of ubiquitin from 
proteins (Lockhart et al., 2004), suggesting that ΔNp63α could theoretically induce the 
de-ubiquitination of PTEN via USP31 rather than inhibit the addition of ubiquitin to 
PTEN. ΔNp63α also potentially regulates the expression of NEDD4 binding partner 1 
(N4BP1). As the name suggests N4BP1 physically interacts with NEDD4-1 thereby 
preventing the binding and ubiquitination of other target proteins. N4BP1 has also been 
shown to bind to other members of the NEDD4 family of ubiquitin ligases, protecting 
p63 and p73 from ITCH mediated degradation (Oberst et al., 2007). While only a mild 
decrease in N4BP1 abundance was observed in one of the four p63-knockdown 
conditions used in the microarray study, the potential positive regulation of N4BP1 by 
ΔNp63α could indirectly inhibit ubiquitination of PTEN by competing with PTEN for a 
number of ubiquitin ligases. The ability of ΔNp63α to regulate N4BP1 or USP31 would 
need to be confirmed first, before attempting to determine if either protein was 
responsible for the reduction in ubiquitination of PTEN caused by ΔNp63α.   
While ubiquitination of PTEN could not be confirmed with exogenous NEDD4-1 
in H1299 cells, in HaCaT cells endogenous NEDD4-1 clearly inhibited PTEN expression 
(Figure 33). Moreover, ΔNp63α was shown to negatively regulate the expression of 
NEDD4-1 in multiple keratinocyte cell lines (Figures 30-31). The inhibition of NEDD4-1 
by ΔNp63α likely serves more as a signaling mechanism than as a means to stabilize 
PTEN protein. This is supported by several pieces of data. First, overexpression of 
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ΔNp63α led to dose-dependent decreases in PTEN protein (Figure 16), which would not 
be expected if ΔNp63α was also indirectly stabilizing PTEN via repression of NEDD4-1. 
Secondly, poly-ubiquitination of PTEN by NEDD4-1 has been shown to be 
predominantly comprised of lysine 63 linked ubiquitin chains (Guo et al., 2012). Lysine 
63 linkages are correlated with signal transduction and proteasome mediated degradation, 
unlike lysine 48 ubiquitin chains which are predominantly degradation signals (Pickart 
and Fushman, 2004; Thrower et al., 2000).  
The ability of NEDD4-1 to ubiquitinate PTEN and ΔNp63α (Bakkers et al., 2005; 
Trotman et al., 2007), combined with the results from this study demonstrating that 
ΔNp63α inhibits NEDD4-1 (Figures 30-31), suggests that ΔNp63α/NEDD4-1/PTEN 
form a natural negative feedback mechanism. This feedback loop serves to keep ΔNp63α 
and NEDD4-1 levels in check so that nuclear PTEN levels are kept low, thereby 
protecting the proliferative capacity of keratinocytes within the basal layer of the 
epidermis. Restriction of NEDD4-1 expression to the basal layer of the epidermis and the 
exclusion of PTEN from the nuclei of basal layer keratinocytes (Figure 37), further 
demonstrates that the inhibition of NEDD4-1 by ΔNp63α is physiologically relevant in 
maintaining homeostasis in normal epidermal tissue. The indirect regulation of PTEN 
ubiquitination via NEDD4-1 and the direct transcriptional repression of PTEN by 
ΔNp63α may also be separated from each other temporally. The experiments performed 
in this dissertation do not address the kinetics of the direct and indirect regulation of 
PTEN by ΔNp63α, making it possible that they do not occur simultaneously as implied in 
the simplified model shown in Figure 37. It will be intriguing to understand how the 
feedback loop between ΔNp63α/NEDD4-1/PTEN is altered in response to differentiation 
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signals, such as high calcium, since both ΔNp63α and NEDD4-1 expression was mainly 
restricted to proliferative basal layer of the epidermis (Figure 36). High calcium levels 
have been demonstrated to activate NEDD4-1 as well as lead to the degradation of 
ΔNp63α, and may represent a key step in inducing keratinocyte differentiation and the 
development of a stratified epidermis (De Laurenzi et al., 2000; Wang et al., 2010).  
The development of a healthy epidermis also relies on the expression of Akt as 
demonstrated by the hypoplastic skin of Akt1/Akt2 double knockout mice (Peng et al., 
2003).The thin, translucent skin of Akt1/Akt2 knockout mice is caused by reduced 
proliferation of basal layer keratinocytes (Peng et al., 2003). Interestingly, activation of 
Akt has also been shown to lead to nuclear export of PTEN and may also contribute to 
the absence of PTEN from the nuclei of basal layer keratinocytes (Liu et al., 2007). As 
ΔNp63α also regulates the activation of Akt via PTEN (Figure 16), there is likely cross 
talk between the Akt-mediated nuclear export of PTEN and ΔNp63α-mediated inhibition 
of nuclear import of PTEN via NEDD4-1. This is supported by studies show that 
inhibition of Akt signaling reduces NEDD4-1 expression (Ahn et al., 2008). 
Hyperactivation of Akt caused by NEDD4-1 mediated degradation of PTEN has also 
been implicated in keloid formation; an abnormal, and often painful, overgrowth of scar 
tissue (Chung et al., 2011). Additionally, forced expression of Akt in basal layer 
keratinocytes sensitizes mice to two-stage chemical carcinogenesis (Segrelles et al., 
2007). Repression of NEDD4-1 by ΔNp63α may thus serve to limit the ubiquitin 
mediated degradation of PTEN, and subsequent hyperactivation of Akt in skin. Further 
studies will be required to understand the complex interplay between ΔNp63α and 
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NEDD4-1 in regulating the PTEN/Akt axis to control proliferation in normal and 
pathological skin. 
To form a proper epidermis during development, basal progenitor cells undergo 
both symmetric cell divisions parallel to the basement membrane to increase surface area 
as well as asymmetric cell divisions perpendicular to the basement membrane to increase 
thickness of the tissue (Lechler and Fuchs, 2005; Smart, 1970). However, embryos from 
p63 deficient mice exhibit random division orientation (Poulson and Lechler, 2010). It 
has also been demonstrated that PTEN is critical in maintaining spindle orientation 
during metaphase by ensuring appropriate levels and localization of PIP3 to the mid-
cortex (Toyoshima et al., 2007), suggesting that the regulation of PTEN by ΔNp63α is 
essential for proper mitotic spindle orientation in addition to controlling the proliferation 
of keratinocytes. Supporting this hypothesis was the identification of a novel pool of 
PTEN localized to mitotic centrosomes and the ability of ΔNp63α to influence the 
abundance of centrosomal PTEN (Figure 38). The ability of ΔNp63α to control both the 
nuclear and centrosomal levels of PTEN is diagramed in Figure 54. 
Aberrant PTEN expression has also previously been correlated with poor 
prognosis in breast cancers with concomitant up-regulation of many centrosome 
associated proteins (Matsushima-Nishiu et al., 2001; Saal et al., 2007). The studies in 
Figures 45 and 47 demonstrate that both PTEN and Akt coordinate to properly regulate 
centrosome composition during mitosis without significantly affecting steady state levels 
of centrosome associated proteins. In primary keratinocytes knockdown of PTEN 
increased whole cell levels of γ-tubulin and PLK-1 in an Akt-dependent manner and had 
little effect on recruitment of either protein to mitotic centrosomes (Figures 46 and 47). 
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Conversely, knockdown of PTEN reduced centrosomal levels of pericentrin in an Akt-
independent manner (Figures 48 and 49).  
Inhibition of Akt activation with MK2206 reduced the whole cell and centrosome 
levels of PLK-1 and γ-tubulin and also prevented the recruitment of PTEN to mitotic 
centrosomes (Figures 48 and 49). Previous studies have implicated a role for Akt in 
removing the G2/M block caused by DNA damage by preventing the ubiquitination and 
degradation of PLK-1 (Shtivelman, 2003). However, no study to date has specifically 
demonstrated that Akt activity is critical for protein recruitment to centrosomes. It is 
currently unclear how Akt activity is able to influence the localization of PTEN to mitotic 
centrosomes, but one could speculate that Akt-mediated control of either GSK3-β or 
S6K2 could influence recruitment of PTEN since both proteins are known to physically 
interact with PTEN as well as localize to mitotic centrosomes (Al-Khouri et al., 2005; Liu 
et al., 2007; Rossi et al., 2007; Wakefield et al., 2003). 
The ability of Akt and PTEN to regulate centrosome composition during mitosis 
likely contributes to proper spindle formation as demonstrated by the increase in 
centrosome defects caused by the knockdown of PTEN and/or inhibition of Akt with 
MK2206 (Figures 50 and 51). The recruitment of γ-tubulin to the proximal ends of 
centrioles is critical for both centrosome maturation and microtubule nucleation (Fuller et 
al., 1995; O'Toole et al., 2012). However, the ability of centrosomes to nucleate 
microtubules after depletion of PTEN and/or Akt was not evaluated in these experiments 
and would vital for future studies to help identify the exact roles of PTEN and Akt in 
controlling centrosome function during mitosis. This could easily be explored by 
measuring mircotuble regrowth after nocodazole treatment in the presence and absence of 
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MK2206 and siRNA against PTEN. It is possible that PTEN may directly influence 
centrosome function by modulating PI3K and Akt activity at the centrosomes in addition 
to the plasma membrane, as both PI3K and Akt have been reported to localize to 
centrosomes in other cell lines (Kalous et al., 2006; Kapeller et al., 1995; Lelievre et al., 
2008).  
Akt inhibitors in addition to MK2206 have been shown to cause spindle 
abnormalities during mitosis (Liu et al., 2008), but the studies in Figures 46 and 48 
provide the first evidence that PTEN and Akt play a direct role in controlling centrosome 
composition during mitosis. Because of the direct effects on recruiting PTEN and PLK-1 
to mitotic centrosomes in addition to the traditional growth suppressive effects of Akt 
inhibition, combinatorial therapies of MK2206 with other mitotic inhibitors may prove 
extremely beneficial in cancer treatment. The potential therapeutic value of centrosomal 
PTEN and its regulation by Akt activity warrants future studies.  
C. Conclusions. 
ΔNp63α has been called the master regulator of epithelial stem cells, controlling 
keratinocyte growth and the proper development of a stratified epidermis. The studies 
presented in this dissertation demonstrate that ΔNp63α is able to maintain the 
proliferative potential of keratinocytes by activating Akt through transcriptional 
repression of PTEN. ΔNp63α was also shown to inhibit the nuclear localization of PTEN, 
which may further the increase the proliferative potential of basal layer keratinocytes 
since nuclear PTEN is associated with G1 arrest (Chung and Eng, 2005; Ginn-Pease and 
Eng, 2003). Inhibition of NEDD4-1 by ΔNp63α was implicated in reducing the 
ubiquitination of PTEN, thereby preventing its import into the nucleus. The studies 
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presented here also identify a novel pool of PTEN that is localized to centrosomes only 
during mitosis. Coordinated control of both Akt and PTEN regulate centrosome 
composition and integrity during mitosis and provides insight into how PTEN functions 
as a multifaceted tumor suppressor. The importance of the ΔNp63α/PTEN/Akt signaling 
loop in epidermal biology was highlighted by the significant disruption of ΔNp63α and 
PTEN levels in non-melanoma skin cancers. Altogether, these studies provide important 
molecular insight into the control of keratinocyte proliferation by the ΔNp63α-PTEN-Akt 
signaling loop.  
D. Future Directions. 
 The studies presented in this dissertation provide the framework for understanding 
the development of NMSC by elucidating how ΔNp63α controls keratinocyte 
proliferation through regulating the expression and localization of PTEN. There is 
however, much more work to be done before this information can be applied to in a 
clinical setting. For instance, the balance between ΔNp63α and PTEN was shown to be 
critical for controlling Akt activation (Figure 18) and that this balance is disrupted in 
NMSC (Figure 23); could the ΔNp63α/PTEN/Akt axis be a potential target for 
pharmacological intervention in the treatment of NMSC? The Akt inhibitor MK2206, 
which was demonstrated here to have novel effects on the composition (Figure 48) and 
quality of centrosomes (Figure 50), is already in phase II clinical trials for other solid 
cancers (Institute, 2012a; Institute, 2012b). Since MK2206 is currently delivered 
intravenously, would topical inhibition of Akt with MK2206 be sufficient to treat 
NMSC? Could MK2206 be used in combination with microtubule destabilizing agents to 
selectively target cancer cells, which typically display centrosome abnormalities and 
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hyperactivation of Akt? All of these questions would need to first be addressed in cell 
culture and animal models before even beginning to design human intervention strategies.  
Additionally, there is still very little known about how the ΔNp63α/PTEN/Akt 
axis is turned off in normal keratinocytes. Identification of the inhibitors of the 
ΔNp63α/PTEN/Akt axis could provide another possible therapeutic option. The induction 
of PTEN by the Egr-1/Arf axis could be another potential pathway for future studies, 
considering that this axis is also regulated Akt (Yu et al., 2009).  
 This dissertation has focused on the involvement of the ΔNp63α/PTEN/Akt in 
NMSC, but this axis may be critical for other epithelial cancers as well. It will be 
important to investigate whether the ΔNp63α/PTEN/Akt axis functions similarly in 
prostate and breast cancers as it does in keratinocytes since the former cancer types have 







Figure 5: Schematic of ΔNp63α-mediated control of PTEN subcellular localization. 
ΔNp63α transcriptionally represses NEDD4-1, inhibiting the ubiquitination and 
subsequent nuclear translocation of PTEN. ΔNp63α also transcriptionally represses 
PTEN, which can inhibit the amount of PTEN available for localization to mitotic 
centrosomes. PTEN can indirectly affect the phosphorylation and activation of Akt. Both 
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